var title_f11_13_11472="Gastric erosion";
var content_f11_13_11472=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F76700&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F76700&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Band erosion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 454px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Band erosion through the wall of the stomach is thought to occur as a result of either gastric wall ischemia from an excessively tight band, mechanical trauma related to the band buckle or thermal trauma from electrosurgical energy sources used during band placement.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Jones DB, Schneider BE, Olbers T. Atlas of Metabolic and Weight Loss Surgery. Cine-Med, North Woodbury, Connecticut 2010. Copyright &copy; 2010 Cine-Med.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_13_11472=[""].join("\n");
var outline_f11_13_11472=null;
var title_f11_13_11473="Cefpirome: International drug information";
var content_f11_13_11473=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Cefpirome: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F1978208\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Cefrom (AT, AU, BE, BR, CH, FI, FR, GB, HR, LU, MX, NL);",
"     </li>",
"     <li>",
"      Keiten (JP)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list synlist drugH1Div drugBrandNames\" id=\"F1978194\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Index Terms",
"    </span>",
"    <ul>",
"     <li>",
"      Cefpirome sulphate",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1978200\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Cephalosporin (Fourth Generation)",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F1978203\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Lower respiratory tract infections, complicated upper and lower urinary tract infections, septicemia, bacteremia, and neutropenic fever caused by susceptible organisms",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F1978197\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults: I.V.: 1-2 g every 12 hours; maximum daily dose: 4 g",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in renal impairment:",
"     </b>",
"     Decrease dose if Cl",
"     <sub>",
"      cr",
"     </sub>",
"     is &lt;50 mL/minute",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821229\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F1978202\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection, powder for reconstitution: 0.5 g, 1 g, 2 g",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10353 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-71969A6E96-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_13_11473=[""].join("\n");
var outline_f11_13_11473=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978208\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978194\">",
"      Index Terms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978200\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978203\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978197\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821229\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978202\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10353\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10353|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_13_11474="Patient information: Kidney cancer (The Basics)";
var content_f11_13_11474=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15490\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/28/27072\">",
"         Anatomy of the urinary tract",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?36/16/37121\">",
"         Patient information: What are clinical trials? (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?9/53/10066\">",
"         Patient information: Blood in the urine (hematuria) in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?29/53/30546\">",
"         Patient information: Renal cell carcinoma (kidney cancer) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Kidney cancer (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/kidney-cancer-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H539738316\">",
"      <span class=\"h1\">",
"       What is kidney cancer?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Kidney cancer happens when normal cells in the kidney change into abnormal cells and grow out of control (",
"      <a class=\"graphic graphic_figure graphicRef79864 \" href=\"UTD.htm?26/28/27072\">",
"       figure 1",
"      </a>",
"      ). People have two kidneys, one on each side of the mid-back. The kidneys&rsquo; job is to filter the blood and remove waste and excess salt and water. Urine is made up of these ingredients.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H539738323\">",
"      <span class=\"h1\">",
"       What are the symptoms of kidney cancer?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Kidney cancer may not cause any symptoms at first. When it does cause symptoms, it can cause:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Blood in the urine",
"       </li>",
"       <li>",
"        Pain on either side of your lower back, in your side, or in your stomach",
"       </li>",
"       <li>",
"        A lump in your belly or on the side of your back",
"       </li>",
"       <li>",
"        Weight loss that you cannot explain",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      These symptoms can also be caused by conditions that are not cancer. But if you have these symptoms, you should be checked by a doctor or nurse.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H539738330\">",
"      <span class=\"h1\">",
"       Is there a test for kidney cancer?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If you have symptoms of kidney cancer, your doctor or nurse might order a test to check your kidneys. These tests can show tumors or abnormal growths. They create images of your kidneys in different ways, and they include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Ultrasound (uses sound waves to create images)",
"       </li>",
"       <li>",
"        CT scan (is a type of X-ray)",
"       </li>",
"       <li>",
"        MRI (uses magnets to create images)",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H539738337\">",
"      <span class=\"h1\">",
"       What is kidney cancer staging?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Cancer staging is a way in which doctors find out how far a cancer has spread.",
"     </p>",
"     <p>",
"      The right treatment for you will depend a lot on the stage of your cancer.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H539738344\">",
"      <span class=\"h1\">",
"       How is kidney cancer treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;People with kidney cancer often have one or both of the following treatments:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         Surgery",
"        </strong>",
"        &ndash; Kidney cancer is usually treated with surgery to remove the cancer. To do this, a surgeon can remove either all or part of the affected kidney. The decision about how much of the affected kidney to remove depends on different things, including how well the other kidney works.",
"        <br/>",
"        <br/>",
"        If the cancer-free kidney is healthy, it can do the work of both kidneys. In this case, the surgeon removes the whole cancerous kidney. But if the cancer-free kidney is not healthy (for example, because it has been damaged by diabetes), it cannot take over for both kidneys. In this case, the surgeon might remove only the part of the cancerous kidney.",
"       </li>",
"       <li>",
"        <strong>",
"         Medicines",
"        </strong>",
"        &ndash; Different medicines can also be used to treat kidney cancer. Doctors can prescribe these medicines in addition to or instead of surgery. The medicines can:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Help your body&rsquo;s infection-fighting system attack the cancer cells",
"       </li>",
"       <li>",
"        Slow or stop the growth of the cancer",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H539738351\">",
"      <span class=\"h1\">",
"       What happens after treatment?",
"      </span>",
"      &nbsp;&mdash;&nbsp;After treatment, you will be checked every so often to see if the cancer comes back. Follow up tests can include exams, lab tests, and X-ray tests.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H539738358\">",
"      <span class=\"h1\">",
"       What happens if the cancer comes back or spreads?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If the cancer comes back or spreads, you might have more surgery or receive more medicine.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H539738365\">",
"      <span class=\"h1\">",
"       What else should I do?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It is important to follow all your doctor&rsquo;s instructions about visits and tests. It&rsquo;s also important to talk to your doctor about any side effects or problems you have during treatment.",
"     </p>",
"     <p>",
"      Getting treated for kidney cancer involves making many choices, such as which type of surgery to have or which medicine to take.",
"     </p>",
"     <p>",
"      Always let your doctors and nurses know how you feel about a treatment. Any time you are offered a treatment, ask:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        What are the benefits of this treatment? Is it likely to help me live longer? Will it reduce or prevent symptoms?",
"       </li>",
"       <li>",
"        What are the downsides to this treatment?",
"       </li>",
"       <li>",
"        Are there other options besides this treatment?",
"       </li>",
"       <li>",
"        What happens if I do not have this treatment?",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H539738372\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/16/37121?source=see_link\">",
"       Patient information: What are clinical trials? (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?9/53/10066?source=see_link\">",
"       Patient information: Blood in the urine (hematuria) in adults (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?29/53/30546?source=see_link\">",
"       Patient information: Renal cell carcinoma (kidney cancer) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?11/13/11474?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15490 Version 3.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-89.32.226.102-D86B8ADF8C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_13_11474=[""].join("\n");
var outline_f11_13_11474=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H539738316\">",
"      What is kidney cancer?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H539738323\">",
"      What are the symptoms of kidney cancer?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H539738330\">",
"      Is there a test for kidney cancer?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H539738337\">",
"      What is kidney cancer staging?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H539738344\">",
"      How is kidney cancer treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H539738351\">",
"      What happens after treatment?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H539738358\">",
"      What happens if the cancer comes back or spreads?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H539738365\">",
"      What else should I do?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H539738372\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15490\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/28/27072\">",
"      Anatomy of the urinary tract",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/53/10066?source=related_link\">",
"      Patient information: Blood in the urine (hematuria) in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?29/53/30546?source=related_link\">",
"      Patient information: Renal cell carcinoma (kidney cancer) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/16/37121?source=related_link\">",
"      Patient information: What are clinical trials? (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_13_11475="Patient information: Lung cancer screening (The Basics)";
var content_f11_13_11475=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?9/63/10227\">",
"         Patient information: Cancer screening (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?34/34/35363\">",
"         Patient information: Lung cancer (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?3/44/3779\">",
"         Patient information: Non-small cell lung cancer (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?17/46/18146\">",
"         Patient information: Quitting smoking (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?23/38/24162\">",
"         Patient information: Small cell lung cancer (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?5/28/5570\">",
"         Patient information: Lung cancer prevention and screening (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?1/3/1076\">",
"         Patient information: Lung cancer risks, symptoms, and diagnosis (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?40/22/41314\">",
"         Patient information: Non-small cell lung cancer treatment; stage I to III cancer (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?16/63/17396\">",
"         Patient information: Non-small cell lung cancer treatment; stage IV cancer (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?19/13/19670\">",
"         Patient information: Quitting smoking (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?22/8/22659\">",
"         Patient information: Small cell lung cancer treatment (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Lung cancer screening (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/lung-cancer-screening-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H3911672\">",
"      <span class=\"h1\">",
"       What is lung cancer screening?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Lung cancer screening is a way in which doctors check the lungs for early signs of cancer in people who have no symptoms of lung cancer. For now, doctors are not sure how useful screening is for preventing cancer deaths, or who (if anyone) should be screened. They have been studying chest x-rays and &ldquo;low dose CT scans&rdquo; to see if they are good screening tools. (CT stands for &ldquo;computed tomography.&rdquo;) A low-dose CT scan uses much less radiation than a normal CT scan and shows a more detailed image of your lungs than a standard x-ray. It turns out that x-rays do not work for screening. Low-dose CT scans, on the other hand, might be helpful screening tools for some people at high risk of lung cancer.",
"     </p>",
"     <p>",
"      The goal of lung cancer screening is to find cancer early, before it has a chance to grow, spread, or cause problems. One large study found that smokers who were screened with low-dose CT scans were less likely to die of lung cancer than those who were screened with standard x-ray. Even so, experts are not yet ready to recommend low-dose CT scans for all heavy smokers. That&rsquo;s because it&rsquo;s unclear whether screening outside of a research study&mdash;in the &ldquo;real world&rdquo;&mdash;would work as well. Plus, screening comes with certain risks, including the need for more tests if a person has an abnormal screening test.",
"     </p>",
"     <p>",
"      The best way to lower your chances of getting or dying from lung cancer is to quit smoking. It does not matter how much or how long you have smoked. Quitting now will reduce your chances not only of lung problems, but also of heart disease and many forms of cancer.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H3911687\">",
"      <span class=\"h1\">",
"       Can I be screened with a standard x-ray instead of a low-dose CT scan?",
"      </span>",
"      &nbsp;&mdash;&nbsp;No. Some doctors recommend that heavy smokers get a chest x-ray once a year to check for cancer, but there is no proof that this helps extend life. Experts do NOT recommend chest x-rays as a way to screen for lung cancer. &nbsp; &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H3911702\">",
"      <span class=\"h1\">",
"       Who should be screened for lung cancer?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It is not clear who, if anyone, should be screened for lung cancer. For now, experts recommend that people who have smoked heavily for years discuss the pros and cons of screening with their doctor. Then they can decide, with their doctor&rsquo;s help, if screening is right for them.",
"     </p>",
"     <p>",
"      The decision to be screened should take these things into account:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Your general health and level of risk &ndash; Your level of risk depends mostly on how much and how long you have smoked, and on whether you still smoke.",
"       </li>",
"       <li>",
"        The costs involved in screening &ndash; It&rsquo;s not yet clear whether insurance companies will pay for screening or the follow-up tests that are needed if a scan is abnormal. If you are thinking about screening, ask your doctor&rsquo;s office what you might have to pay.",
"       </li>",
"       <li>",
"        Access to experts in lung cancer screening &ndash; Not all doctors are experts at reading low-dose CT scans, or in deciding what to do if a test is abnormal. For screening to be helpful, a very experienced person must read the scan. Plus, it&rsquo;s important that any abnormal results be managed by a doctor who is an expert at diagnosing lung cancer.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H3911717\">",
"      <span class=\"h1\">",
"       What are the benefits of being screened for lung cancer?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The main benefit of screening is that it helps doctors find cancer early, when it should be easier to treat. This might lower your chances of dying of lung cancer.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H3911732\">",
"      <span class=\"h1\">",
"       What are the drawbacks to being screened for lung cancer?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The drawbacks include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        False positives &mdash; Low dose CT scans sometimes give &ldquo;false positives,&rdquo; meaning they suggest a person might have cancer when he or she does not. This can lead to unneeded worry and to more tests. For example, people who have false positives sometimes have follow-up full-dose CT scans, which expose them to more radiation. They sometimes also need a lung biopsy, which is a procedure to remove a small sample of lung tissue. This procedure can be painful and lead to problems, such as bleeding or a collapsed lung.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Radiation exposure &mdash; Like all x-rays, CT scans expose you to some radiation. Although the radiation dose from the first screening CT scan is low, you would need to have a scan every year, so your exposure would add up. Plus, if you have an abnormal result, you could end up having full dose CT scans.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H3911747\">",
"      <span class=\"h1\">",
"       What happens during a low-dose CT scan?",
"      </span>",
"      &nbsp;&mdash;&nbsp;When you have a low-dose CT scan, you lie on a table that slides into a machine. The machine is shaped like a giant donut and you slide through the large hole in the center. As you slide through, the machine takes pictures of the inside of your body. The process takes several minutes and is painless.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H3911762\">",
"      <span class=\"h1\">",
"       What happens after a low-dose CT scan?",
"      </span>",
"      &nbsp;&mdash;&nbsp;After a low-dose CT scan, you should get a phone call or letter with your results. If you do not hear back about your results in about 2 weeks, call your doctor or nurse's office. Do not assume that your scan was normal if you hear nothing.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H3911779\">",
"      <span class=\"h1\">",
"       What if my CT scan is abnormal?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If your scan is abnormal, don't panic. More than 95 out of 100 people with an abnormal scan turn out NOT to have lung cancer. You will need more tests to find out whether you actually have cancer.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H3911794\">",
"      <span class=\"h1\">",
"       How often should I have a low-dose CT scan?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you and your doctor decide that screening is right for you, you will need to have a low-dose CT scan once a year.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H3911809\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?17/46/18146?source=see_link\">",
"       Patient information: Quitting smoking (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/63/10227?source=see_link\">",
"       Patient information: Cancer screening (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?34/34/35363?source=see_link\">",
"       Patient information: Lung cancer (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?3/44/3779?source=see_link\">",
"       Patient information: Non-small cell lung cancer (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/38/24162?source=see_link\">",
"       Patient information: Small cell lung cancer (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?19/13/19670?source=see_link\">",
"       Patient information: Quitting smoking (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?5/28/5570?source=see_link\">",
"       Patient information: Lung cancer prevention and screening (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?1/3/1076?source=see_link\">",
"       Patient information: Lung cancer risks, symptoms, and diagnosis (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?40/22/41314?source=see_link\">",
"       Patient information: Non-small cell lung cancer treatment; stage I to III cancer (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?16/63/17396?source=see_link\">",
"       Patient information: Non-small cell lung cancer treatment; stage IV cancer (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?22/8/22659?source=see_link\">",
"       Patient information: Small cell lung cancer treatment (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?11/13/11475?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16561 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-110.170.48.130-F42F8ABDFE-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_13_11475=[""].join("\n");
var outline_f11_13_11475=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3911672\">",
"      What is lung cancer screening?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3911687\">",
"      Can I be screened with a standard x-ray instead of a low-dose CT scan?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3911702\">",
"      Who should be screened for lung cancer?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3911717\">",
"      What are the benefits of being screened for lung cancer?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3911732\">",
"      What are the drawbacks to being screened for lung cancer?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3911747\">",
"      What happens during a low-dose CT scan?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3911762\">",
"      What happens after a low-dose CT scan?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3911779\">",
"      What if my CT scan is abnormal?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3911794\">",
"      How often should I have a low-dose CT scan?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3911809\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/63/10227?source=related_link\">",
"      Patient information: Cancer screening (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/34/35363?source=related_link\">",
"      Patient information: Lung cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?5/28/5570?source=related_link\">",
"      Patient information: Lung cancer prevention and screening (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/3/1076?source=related_link\">",
"      Patient information: Lung cancer risks, symptoms, and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/44/3779?source=related_link\">",
"      Patient information: Non-small cell lung cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/22/41314?source=related_link\">",
"      Patient information: Non-small cell lung cancer treatment; stage I to III cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?16/63/17396?source=related_link\">",
"      Patient information: Non-small cell lung cancer treatment; stage IV cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/13/19670?source=related_link\">",
"      Patient information: Quitting smoking (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?17/46/18146?source=related_link\">",
"      Patient information: Quitting smoking (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/38/24162?source=related_link\">",
"      Patient information: Small cell lung cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?22/8/22659?source=related_link\">",
"      Patient information: Small cell lung cancer treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_13_11476="Pemphigoid gestationis IF";
var content_f11_13_11476=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F65548&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F65548&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pemphigoid gestationis - direct immunofluorescence",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Direct immunofluorescence microscopy shows linear deposition of C3 along the dermal-epidermal junction.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_13_11476=[""].join("\n");
var outline_f11_13_11476=null;
var title_f11_13_11477="Membranous VSD with aneurysm color";
var content_f11_13_11477=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1182px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/51322/Membr_VSD_aneurysm_movie.mp4?title=Membranous+VSD+with+aneurysm+color\" style=\"width:496px;height:384px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 566px\">",
"   <div class=\"ttl\">",
"    Membranous VSD with aneurysm color",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 546px; height: 397px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <p>",
"     Membranous VSD with apposed \"aneurysm\" tissue is demonstrated in still frames obtained from long axis imaging planes. Movie clip from study of the same patient shows the defect&nbsp;in an apical four chamber&nbsp;view. The color flow jet of residual flow across the VSD is seen exiting into the right ventricle beneath the apposed septal leaflet of the tricuspid valve. The adherent tissue limits flow into the right ventricle, occluding a portion of the defect",
"    </p>",
"    <div class=\"footnotes\">",
"     LV: left ventricle; LA: left atrium; RV: right ventricle; AO: aorta; MV: mitral valve; arrows; VSD.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_13_11477=[""].join("\n");
var outline_f11_13_11477=null;
var title_f11_13_11478="Thiopental: Pediatric drug information";
var content_f11_13_11478=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Thiopental: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?0/63/1015?source=see_link\">",
"    see \"Thiopental: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?36/19/37171?source=see_link\">",
"    see \"Thiopental: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F226996\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Pentothal&reg; [DSC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1055635\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anticonvulsant, Barbiturate",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Barbiturate",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       General Anesthetic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Hypnotic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Sedative",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11445205\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Induction anesthesia: I.V.: 3-4 mg/kg",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1055628\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?0/63/1015?source=see_link\">",
"      see \"Thiopental: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Induction anesthesia: I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants: 5-8 mg/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 1-12 years: 5-6 mg/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &gt;12 years and Adults: 3-5 mg/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maintenance anesthesia: I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 1 mg/kg as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 25-100 mg as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Increased intracranial pressure: Children: I.V.: 1.5-5 mg/kg/dose; repeat as needed to control intracranial pressure; larger doses (30 mg/kg) to induce coma after hypoxic-ischemic injury do not appear to improve neurologic outcome",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Seizures: I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 2-3 mg/kg/dose, repeat as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 75-250 mg/dose, repeat as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Sedation: Rectal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 5-10 mg/kg/dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 3-4 g/dose",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F226979\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution, as sodium:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pentothal&reg;: 250 mg [DSC], 400 mg [DSC], 500 mg [DSC], 1 g [DSC] [contains sodium 105 mg/g]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F226963\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F14960845\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pentothal&reg; (thiopental injection): Hospira Pharmaceuticals, the sole manufacturer, has discontinued all Pentothal&reg; products. Product is currently unavailable in the U.S. and in Canada.",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F227030\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-III",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1055641\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Parenteral: Avoid rapid I.V. injection (may cause hypotension or decreased cardiac output); may administer by intermittent infusion over 10-60 minutes at a maximum concentration of 50 mg/mL",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F227035\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, NS;",
"     <b>",
"      incompatible",
"     </b>",
"     with D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      10",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     NS, LR;",
"     <b>",
"      variable stability (consult detailed reference)",
"     </b>",
"     in D",
"     <sub>",
"      5",
"     </sub>",
"     NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Bivalirudin, fentanyl, furosemide, hetastarch in lactate electrolyte injection (Hextend&reg;), milrinone, nitroglycerin, propofol, ranitidine, remifentanil.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Alfentanil, ascorbic acid, atracurium, atropine, diltiazem, dobutamine, dopamine, ephedrine, epinephrine, fenoldopam, hydromorphone, labetalol, midazolam, nicardipine, norepinephrine, pancuronium, pantoprazole, phenylephrine, succinylcholine, sufentanil, vecuronium.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Cisatracurium, heparin, lidocaine, lorazepam, morphine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Aminophylline, hyaluronidase, neostigmine, pentobarbital, propofol, scopolamine, tubocurarine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Chlorpromazine, dimenhydrinate, diphenhydramine, doxapram, ephedrine, glycopyrrolate, meperidine, morphine, pantoprazole, prochlorperazine edisylate, promethazine, sodium bicarbonate.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Hydrocortisone sodium succinate.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1055631\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Solutions are alkaline and incompatible with drugs with acidic pH, such as succinylcholine, atropine sulfate",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1055640\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Induction of anesthesia; adjunct for intubation in head injury patients; control of convulsive states; treatment of elevated intracranial pressure",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F5174562\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F227034\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Bradycardia, hypotension, syncope",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Agitation, anxiety, ataxia, CNS excitation or depression, confusion, dizziness, drowsiness, hallucinations, &ldquo;hangover&rdquo; effect, headache, hyperkinesia, impaired judgment, insomnia, lethargy, nervousness, nightmares, shivering, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Exfoliative dermatitis, rash, Stevens-Johnson syndrome",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Constipation, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, immune hemolytic anemia (rare), megaloblastic anemia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Pain at injection site, thrombophlebitis with I.V. use",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Oliguria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Apnea (especially with rapid I.V. use), bronchospasm, cough, hypoventilation, laryngospasm, respiratory depression, sneezing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylactic reactions, anaphylaxis, gangrene with inadvertent intra-arterial injection",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1055645\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to thiopental, pentobarbital, any component, or other barbiturates; porphyria (variegate or acute intermittent)",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1055627\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with asthma or pharyngeal infections because cough, laryngospasm, or bronchospasms may occur; use with caution in patients with hypotension, severe cardiovascular disease, hepatic or renal dysfunction; avoid extravasation or intra-arterial injection which may cause necrosis due to pH of 10.6; ensure patient has intravenous access",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300133\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F226972\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetaminophen: Barbiturates may increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Barbiturates may decrease the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Atenolol; Levobunolol; Metipranolol; Nadolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: Barbiturates may increase the metabolism of Calcium Channel Blockers.  Management: Monitor for decreased therapeutic effects of calcium channel blockers with concomitant barbiturate therapy. Calcium channel blocker dose adjustments may be necessary. Nimodipine Canadian labeling contraindicates concomitant use with phenobarbital.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Clevidipine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: May enhance the adverse/toxic effect of Anticonvulsants (Barbiturate). Specifically, osteomalacia and rickets.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Brinzolamide; Dorzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chloramphenicol: Barbiturates may increase the metabolism of Chloramphenicol. Chloramphenicol may decrease the metabolism of Barbiturates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): Barbiturates may diminish the therapeutic effect of Contraceptives (Estrogens). Contraceptive failure is possible.  Management: Use of a non-hormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Progestins): Barbiturates may diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.  Management: Use of alternative, nonhormonal contraceptives is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Barbiturates may decrease the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Barbiturates may increase the metabolism of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disopyramide: Barbiturates may increase the metabolism of Disopyramide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: May decrease the metabolism of Barbiturates. Barbiturates may decrease the serum concentration of Divalproex.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Doxycycline: Barbiturates may decrease the serum concentration of Doxycycline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etoposide: Barbiturates may decrease the serum concentration of Etoposide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etoposide Phosphate: Barbiturates may decrease the serum concentration of Etoposide Phosphate. Barbiturates may increase the metabolism, via CYP isoenzymes, of etoposide phosphate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Felbamate: Barbiturates may decrease the serum concentration of Felbamate. Felbamate may increase the serum concentration of Barbiturates.  Management: Monitor for elevated barbiturate concentrations/toxicity if felbamate is initiated/dose increased, or reduced concentrations/effects if felbamate is discontinued/dose decreased. Refer to phenobarbital dosing guidelines for patients receiving that agent.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Barbiturates may enhance the CNS depressant effect of Fosphenytoin. Barbiturates may decrease the serum concentration of Fosphenytoin. Fosphenytoin may increase the serum concentration of Barbiturates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of Barbiturates. Management: Consider a decrease in the barbiturate dose, as appropriate, when used together with hydroxyzine.  With concurrent use, monitor patients closely for excessive response to the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Nasal): May diminish the therapeutic effect of Anticonvulsants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Systemic): May diminish the therapeutic effect of Anticonvulsants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     LamoTRIgine: Barbiturates may decrease the serum concentration of LamoTRIgine.  Management: See lamotrigine prescribing information for specific age-dependent dosing guidelines regarding concurrent use with a barbiturate, as well as for adjusting lamotrigine dosing if concurrent barbiturate therapy is discontinued.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mefloquine: May diminish the therapeutic effect of Anticonvulsants. Mefloquine may decrease the serum concentration of Anticonvulsants. Management: Mefloquine is contraindicated for malaria prophylaxis in persons with a history of convulsions.  Monitor anticonvulsant concentrations and treatment response closely with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Meperidine: Barbiturates may enhance the CNS depressant effect of Meperidine. Barbiturates may increase serum concentrations of the active metabolite(s) of Meperidine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methadone: Barbiturates may enhance the CNS depressant effect of Methadone. Barbiturates may decrease the serum concentration of Methadone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Barbiturates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May enhance the CNS depressant effect of Barbiturates. Barbiturates may decrease the serum concentration of Phenytoin. Phenytoin may increase the serum concentration of Barbiturates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Primidone: May enhance the adverse/toxic effect of Barbiturates. Primidone is converted to phenobarbital, and thus becomes additive with existing barbiturate therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: Barbiturates may decrease the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pyridoxine: May increase the metabolism of Barbiturates. Apparent in high pyridoxine doses (eg, 200 mg/day)",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Barbiturates may enhance the hepatotoxic effect of QuiNIDine. Barbiturates may decrease the serum concentration of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the metabolism of Barbiturates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Teniposide: Barbiturates may decrease the serum concentration of Teniposide.  Management: Consider alternatives to combined treatment with barbiturates and teniposide due to the potential for decreased teniposide concentrations.  If the combination cannot be avoided, monitor teniposide response closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Barbiturates may decrease the serum concentration of Theophylline Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dyphylline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Barbiturates may enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: Barbiturates may increase the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: May decrease the metabolism of Barbiturates. Barbiturates may decrease the serum concentration of Valproic Acid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Barbiturates may increase the metabolism of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F226974\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1055634\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Respiratory rate, heart rate, blood pressure",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1055639\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Therapeutic:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hypnotic: 1-5 mcg/mL (SI: 4.1-20.7 micromoles/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Coma: 30-100 mcg/mL (SI: 124-413 micromoles/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Anesthesia: 7-130 mcg/mL (SI: 29-536 micromoles/L)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1055626\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ultra-short-acting barbiturate; depresses CNS activity by binding to barbiturate site at GABA-receptor complex enhancing GABA activity; depresses reticular activating system; higher doses may be gabamimetic",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1055643\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Anesthesia effects:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: I.V.: 30-60 seconds",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 5-30 minutes",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1055644\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : Adults: 1.4 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 72% to 86%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: In the liver primarily to inactive metabolites but pentobarbital is also formed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life, adults: 3-11.5 hours (shorter half-life in children)",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1055646\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Accumulation may occur with chronic dosing due to lipid solubility; prolonged recovery occurs due to redistribution of thiopental from fat stores; therefore, thiopental is usually not used for procedures lasting &gt;15-20 minutes; sodium content, injection: 4.9 mEq/g",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12836 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-197.136.42.3-293D88DB16-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_13_11478=[""].join("\n");
var outline_f11_13_11478=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226996\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055635\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11445205\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055628\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226979\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226963\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14960845\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227030\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055641\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227035\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055631\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055640\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5174562\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227034\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055645\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055627\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300133\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226972\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226974\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055634\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055639\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055626\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055643\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055644\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055646\">",
"      Additional Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12836\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12836|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?0/63/1015?source=related_link\">",
"      Thiopental: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?36/19/37171?source=related_link\">",
"      Thiopental: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_13_11479="EPT phenotypes of abnormal propagation";
var content_f11_13_11479=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F86440&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F86440&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 620px\">",
"   <div class=\"ttl\">",
"    Esophageal pressure topography phenotypes of abnormal propagation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 600px; height: 304px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Panel A illustrates a premature contraction defined by a DL of &lt;4.5 s with a normal IRP, the defining feature of DES in the Chicago classification. In this example the CFV is also markedly abnormal with the upper limit of normal being 9 cm/s. Panel B also illustrates a premature contraction, but in this case the CFV is normal. In Panel C, there is a normal DL but rapid CFV. Note how this is associated with a large (5.5 cm) break in the 30 mmHg isobaric contour and an otherwise normal appearing fragment of peristalsis. Panel C is categorized as borderline motor function in the Chicago classification whereas this would have been defined as DES utilizing conventional manometric criteria.",
"    <div class=\"footnotes\">",
"     DES: distal esophageal spasm; UES: upper esophageal sphincter; CDP: contractile deceleration point; EGJ: esophagogastric junction; CFV: contractile front velocity; DL: distal latency.",
"    </div>",
"    <div class=\"reference\">",
"     Original figure modified for this publication. Pandolfino JE, Roman S, Carlson D, et al. Distal esophageal spasm in high-resolution esophageal pressure topography: defining clinical phenotypes. Gastroenterology 2011; 141:469. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_13_11479=[""].join("\n");
var outline_f11_13_11479=null;
var title_f11_13_11480="Prediction of preeclampsia";
var content_f11_13_11480=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prediction of preeclampsia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/13/11480/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/13/11480/contributors\">",
"     Errol R Norwitz, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/13/11480/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/13/11480/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/13/11480/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/13/11480/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/13/11480/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preeclampsia refers to the onset of hypertension and proteinuria after 20 weeks of gestation in a previously normotensive woman (",
"    <a class=\"graphic graphic_table graphicRef79977 \" href=\"UTD.htm?4/31/4603\">",
"     table 1",
"    </a>",
"    ). The clinical manifestations of preeclampsia can appear anytime from the second trimester to the first few weeks postpartum; however, the initial pathological changes begin in the late first trimester and consist of abnormal remodeling of the spiral arteries. Severe preeclampsia can result in pulmonary edema cerebral hemorrhage, hepatic failure, renal failure, seizures (eclampsia), disseminated intravascular coagulation (primarily with abruption), and maternal death.",
"    <span class=\"nowrap\">",
"     Fetal/neonatal",
"    </span>",
"    consequences include preterm birth, stillbirth, growth restriction, and admission to a neonatal intensive care unit. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/61/34777?source=see_link\">",
"     \"Pathogenesis of preeclampsia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A good test for predicting women who will develop preeclampsia should be simple, rapid, noninvasive, inexpensive, easy to perform, and should not expose the patient to discomfort or risk [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11480/abstract/1\">",
"     1",
"    </a>",
"    ]. The technology should be widely available and the results reproducible and reliable, with a high likelihood ratio for a positive test (&gt;15) and a low likelihood ratio for a negative result (&lt;0.1) and good sensitivity and specificity. Ideally, it should provide an opportunity for intervention to prevent development of the disease, or at least result in better maternal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fetal outcomes.",
"   </p>",
"   <p>",
"    The ability to predict preeclampsia is currently of limited benefit because neither the development of the disorder nor its progression from mild to severe disease can be prevented in most patients, and there is no cure except delivery. Nevertheless, the accurate identification of women at risk, early diagnosis, and prompt and appropriate management (eg, antenatal corticosteroids for fetal lung maturation, treatment of severe hypertension, early delivery) may improve maternal outcome, and possibly perinatal outcome, as well.",
"   </p>",
"   <p>",
"    Currently, there are no clinically available tests that perform well in distinguishing women who will develop preeclampsia from those who will not [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11480/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. In addition to developing novel approaches to prediction of preeclampsia, future studies should distinguish the ability of screening tests to predict mild versus severe preeclampsia and early versus term preeclampsia.",
"   </p>",
"   <p>",
"    Screening women to identify those most likely to develop preeclampsia will be reviewed here. Additional issues related to diagnosis and management of preeclampsia are discussed separately.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27978?source=see_link\">",
"       \"Preeclampsia: Clinical features and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/23/21882?source=see_link\">",
"       \"Preeclampsia: Management and prognosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41609?source=see_link\">",
"       \"Prevention of preeclampsia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PREDICTION OF PREECLAMPSIA BASED ON RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple risk factors for development of preeclampsia have been described (",
"    <a class=\"graphic graphic_table graphicRef61266 \" href=\"UTD.htm?43/39/44667\">",
"     table 2",
"    </a>",
"    ), generally with relative risks of 1.5 to 9.7 in meta-analyses and systematic reviews [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11480/abstract/4\">",
"     4",
"    </a>",
"    ]. Ethnicity may also be a risk factor (compared to white women, the risk of preeclampsia appears to be higher in African-American women and lower in Asian and Hispanic women) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11480/abstract/5\">",
"     5",
"    </a>",
"    ]. Most risk factors are not modifiable.",
"   </p>",
"   <p>",
"    Assessment of risk factors has been proposed to aid in developing an antenatal care plan, particularly for women who are planning to receive pregnancy care and deliver in a low-risk setting (eg, midwifery practice, birthing center, home birth). Guidelines in the UK recommend that women with risk factors for preeclampsia be offered consultation early in pregnancy with a physician with expertise in management of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11480/abstract/4\">",
"     4",
"    </a>",
"    ]. Other potential interventions include increased frequency of antenatal visits, education about the signs and symptoms of preeclampsia, and baseline laboratory evaluation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27978?source=see_link&amp;anchor=H3#H3\">",
"     \"Preeclampsia: Clinical features and diagnosis\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TESTS UNDER INVESTIGATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based on data from patients with established disease, a wide variety of markers have been proposed to detect subgroups of women at high risk of developing preeclampsia. Because the prevalence of preeclampsia in the general obstetrical population is relatively low (1 to 7 percent), a test would need very high sensitivity and specificity to confidently predict or exclude development of the disease. Systematic reviews of studies that evaluated clinically available tests have generally concluded that these tests were not sufficiently accurate (high sensitivity and specificity) for screening the general obstetrical population and that the overall methodological quality of available studies was generally poor [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11480/abstract/6-9\">",
"     6-9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The predictive value of measuring angiogenic factors was not evaluated in these systematic reviews. This approach appears promising and is discussed below. Another exception is uterine artery Doppler velocimetry; the predictive value of this test is controversial and is also discussed below [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11480/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Limitations of available data",
"    </span>",
"    &nbsp;&mdash;&nbsp;The utility of systematic reviews of tests for prediction of preeclampsia is limited by several factors, including (1) variation in the definition of preeclampsia , which introduces heterogeneity in classification of the syndrome; (2) variation in",
"    <span class=\"nowrap\">",
"     inclusion/exclusion",
"    </span>",
"    criteria, which also increases heterogeneity; (3) variation in the criteria defining level of risk (low versus high) of a given population (some studies of low-risk populations have had preeclampsia incidence rates higher than high-risk populations in other studies); (4) multiplicity of potential tests, test combinations, and timing of screening during pregnancy; and (5) lack of inclusion of specific important information or flawed study design",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    conduct [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11480/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Levels of angiogenic factors in blood and urine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data from both human and animal models suggest that aberrant expression of angiogenic modulators is important in the pathogenesis of diffuse endothelial injury and increased capillary permeability, which are the pathophysiologic hallmarks of preeclampsia. The angiogenic factors of interest include vascular endothelial growth factor (VEGF) and placental growth factor (PlGF), as well as two anti-angiogenic proteins, soluble endoglin (sEng) and the truncated form of the full-length VEGF receptor type-1 (Flt1), known as soluble fms-like tyrosine kinase 1 (sFlt-1). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/61/34777?source=see_link\">",
"     \"Pathogenesis of preeclampsia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ischemic trophoblast has been shown to increase production of anti-angiogenic proteins (sEng, sFlt1) and reduce production of angiogenic proteins (VEGF, PIGF). Alterations in absolute levels of VEGF [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11480/abstract/12-15\">",
"     12-15",
"    </a>",
"    ], PlGF [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11480/abstract/12,13\">",
"     12,13",
"    </a>",
"    ], sFlt-1 [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11480/abstract/12,13,16-22\">",
"     12,13,16-22",
"    </a>",
"    ], and sEng [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11480/abstract/18-21,23\">",
"     18-21,23",
"    </a>",
"    ] in maternal blood and urine precede the onset of clinical preeclampsia by several weeks to months, correlate with disease severity, and normalize after delivery. However, blood and urine levels of these factors have not been proven to be clinically useful for prediction of preeclampsia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4144786\">",
"    <span class=\"h3\">",
"     Blood",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systematic review evaluated 22 case-control and 12 cohort studies that tested PlGF, VEGF, sFLT1, or sENG alone or in combination in the",
"    <span class=\"nowrap\">",
"     serum/plasma",
"    </span>",
"    of pregnant women before clinical onset of preeclampsia and before 30&nbsp;weeks of gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11480/abstract/24\">",
"     24",
"    </a>",
"    ]. The concentration of PlGF (27 studies) and VEGF (3 studies) was lower in women who developed preeclampsia and the concentration of sFLT1 (19 studies) and sENG (10 studies) was higher in these women; the summary diagnostic odds ratios were: PlGF 9.0 (95% CI 5.6&ndash;14.5), sFLT1 6.6 (95% CI 3.1&ndash;13.7), sENG 4.2 (95% CI 2.4&ndash;7.2), which correspond to sensitivities of 32, 26 and 18 percent, respectively, with a 5 percent false-positive rate. Although the concentration of these factors before 30 weeks of gestation was predictive of development of preeclampsia, test performance was too poor to recommend use of these tests for screening. Most of the markers did not perform well in the first half of pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4144793\">",
"    <span class=\"h3\">",
"     Urine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Less data are available on the clinical value of urine testing.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The effectiveness of urinary PIGF for the prediction of preeclampsia was demonstrated in a nested case control study [",
"      <a class=\"abstract\" href=\"UTD.htm?11/13/11480/abstract/25\">",
"       25",
"      </a>",
"      ] that used stored urine specimens from women who had been enrolled in the Calcium for Preeclampsia Prevention (CPEP) trial [",
"      <a class=\"abstract\" href=\"UTD.htm?11/13/11480/abstract/26\">",
"       26",
"      </a>",
"      ], which included healthy nulliparous women with singleton pregnancies followed from between 13 and 21 weeks of gestation until 24 hours postpartum. Urine samples were collected before enrollment, at 26 to 29 weeks of gestation, at 36 weeks, and at onset of preeclampsia. The major findings were as follows:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Baseline urinary PIGF levels at 8 to 21 weeks of gestation were not significantly different between women who developed preeclampsia and those who remained normotensive.",
"     </li>",
"     <li>",
"      Urinary PlGF increased during the first two trimesters, peaked at 29 to 32 weeks, and decreased thereafter in both groups. However, women who went on to develop preeclampsia had lower levels of PIGF than controls at each sampling interval from 25 weeks through onset of disease.",
"     </li>",
"     <li>",
"      At 21 to 32 weeks, a PIGF concentration in the lowest quartile (less than 118",
"      <span class=\"nowrap\">",
"       pg/mL)",
"      </span>",
"      was highly predictive of development of preeclampsia before term (OR 22.5, 95% CI 7.4-67.8), but less predictive of term preeclampsia (OR 2.2, 95% CI 1.2-4.3).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      sEng is present and elevated in the urine of women who develop preterm preeclampsia; however, urinary sEng has only limited ability to determine the severity of preeclampsia and to distinguish between preeclampsia and chronic hypertension [",
"      <a class=\"abstract\" href=\"UTD.htm?11/13/11480/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Ratio of angiogenic factors in blood and urine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fractional excretion modeling (ratios) offer advantages over absolute levels of urinary angiogenic factors for identifying women at risk for developing preeclampsia since ratios account for dilutional effects [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11480/abstract/21,22,28,29\">",
"     21,22,28,29",
"    </a>",
"    ]. One study that measured levels of angiogenic factors prospectively in matched serum and urine samples from a cohort of 42 preeclamptic women and 13 healthy pregnant controls demonstrated that preeclampsia was associated with increased fractional excretion of angiogenic factors, especially VEGF [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11480/abstract/28\">",
"     28",
"    </a>",
"    ]. This model suggested that measurement of sFlt-1:VEGF (or sFlt-1:PlGF) ratios was superior to absolute levels of angiogenic factors or measurement of urinary protein in identifying women at risk for developing preeclampsia. Incorporation of urinary sEng levels into this fractional excretion model does not appear to improve the ability of this test to identify women at risk of developing preeclampsia [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11480/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although such tests appear promising, it should be remembered that the role of these proteins in the pathogenesis of preeclampsia and as markers of incipient disease remain investigational. Prospective longitudinal studies with measurements throughout pregnancy are needed to assess the validity of these observations and determine how this information can be used clinically. The World Health Organization (WHO) has initiated a large prospective, observational study in developing nations to evaluate the usefulness of screening women for angiogenic proteins for the prediction of preeclampsia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Uterine artery Doppler velocimetry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Impedance to flow in the uterine arteries normally decreases as pregnancy progresses. Increased impedance for gestational age is an early radiographic feature of preeclampsia, and likely reflects high downstream resistance due to defective differentiation of trophoblast, which leads to defective invasion of spiral arteries and failure of these vessels to transform into low resistance vessels.",
"   </p>",
"   <p>",
"    Two types of uterine artery Doppler waveform analysis techniques have emerged for prediction of preeclampsia, as well as other disorders associated with impaired placentation (eg, fetal growth restriction, pregnancy loss): (1) presence or absence of diastolic notching (unilateral, bilateral) of the uterine arcuate vessels, and (2) flow waveform ratios (eg, high resistance or pulsatility index,",
"    <span class=\"nowrap\">",
"     systolic/diastolic",
"    </span>",
"    ratio).",
"   </p>",
"   <p>",
"    Studies of uterine artery Doppler velocimetry for prediction of preeclampsia are difficult to compare because investigators have used different Doppler sampling techniques, definitions of abnormal flow velocity waveform, populations, gestational age at examination, and criteria for the diagnosis of preeclampsia.",
"   </p>",
"   <p>",
"    The use of uterine artery Doppler velocimetry for prediction of preeclampsia was best illustrated in a systematic review of 74 studies including almost 80,000 women [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11480/abstract/10\">",
"     10",
"    </a>",
"    ]. These studies involved 15 uterine artery Doppler indices and women at low or high risk of developing preeclampsia. The authors concluded:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Uterine artery Doppler ultrasonography was more accurate for prediction of preeclampsia when performed in the second trimester rather than in the first-trimester.",
"     </li>",
"     <li>",
"      Women at low risk of developing preeclampsia:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The overall risk of preeclampsia was best predicted by the presence of second trimester elevation of pulsatility index accompanied by uterine artery notching (sensitivity 23 percent, specificity 99 percent, positive likelihood ratio (+LR) 7.5, negative likelihood ratio (-LR) 0.59).",
"     </li>",
"     <li>",
"      The risk of severe preeclampsia was best predicted by either a second trimester elevated pulsatility index (sensitivity 78 percent, specificity 95 percent, +LR 15.6, -LR 0.23) or bilateral notching (sensitivity 65 percent, specificity 95 percent, +LR 13.4, -LR 0.37).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Women at high risk of developing preeclampsia:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The overall risk of preeclampsia was best predicted by the presence of a second trimester elevation of pulsatility index accompanied by uterine artery notching (sensitivity 19 percent, specificity 99 percent, +LR 21, -LR 0.82).",
"     </li>",
"     <li>",
"      The risk of severe preeclampsia was best predicted by second trimester elevated resistance index (sensitivity 80 percent, specificity 78 percent, +LR 3.7, -LR 0.26).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although meta-analyses show that uterine artery Doppler analysis can predict women at increased risk of preeclampsia [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11480/abstract/10,30\">",
"     10,30",
"    </a>",
"    ], we and most experts do not recommend these studies for screening purposes [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11480/abstract/7,31-34\">",
"     7,31-34",
"    </a>",
"    ]. Close clinical monitoring for preeclampsia is already a major component of prenatal care; improved identification of women at increased or decreased risk of a disease that cannot be prevented and has no treatment other than delivery is unlikely to improve maternal or fetal outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11480/abstract/35\">",
"     35",
"    </a>",
"    ]. Furthermore, the false positive rate of this test is quite high [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11480/abstract/33,34\">",
"     33,34",
"    </a>",
"    ], leading to excessive patient anxiety and health care costs. Further research is needed before screening with uterine artery Doppler can be recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Novel approaches",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Combinations of tests",
"      </strong>",
"      &mdash; Several investigators have used combinations of tests to predict preeclampsia. A systematic review found that combinations of markers generally led to an increase in sensitivity",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      specificity compared with single markers [",
"      <a class=\"abstract\" href=\"UTD.htm?11/13/11480/abstract/11\">",
"       11",
"      </a>",
"      ]. In low-risk populations, combinations including placental protein 13, pregnancy-associated plasma protein A, and a disintegrin and metalloprotease-12 (ADAM12) measured in the first or early second trimester plus uterine artery Doppler in the second trimester appear promising, with sensitivity 60 to 80 percent and specificity greater than 80 percent. In high-risk populations, the combination of placental protein 13 plus pulsatility index in the first trimester had 90 percent sensitivity and 90 percent specificity in a single small study limited to severe preeclampsia.",
"      <br/>",
"      <br/>",
"      A promising large study attempted to develop a model for predicting preeclampsia in 7797 women with singleton pregnancies at 11 to 13 weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?11/13/11480/abstract/36\">",
"       36",
"      </a>",
"      ]. &nbsp;Preeclampsia developed in 157 women; 34 of these women developed the disease at less than 34 weeks. Using logistic regression analysis, the authors developed an algorithm to predict early preeclampsia using the logs of uterine artery pulsatility index, mean arterial pressure, serum pregnancy-associated plasma protein-A, serum free placental growth factor, as well as body mass index, presence of nulliparity, and history of previous preeclampsia. At a 5 percent false-positive rate (ie, normotensive deliveries), 476 women tested positive for early preeclampsia and 32 of these women developed the disease. Of the 7321 women who tested negative for early preeclampsia, two developed early disease. The sensitivity of this model was 94.1 percent and specificity was 94.3 percent, the LR+ was 16.5 and LR- was 0.06. The reliability of this model needs to be tested by other investigators and in other populations.",
"     </li>",
"     <li>",
"      <strong>",
"       Proteomic profiling",
"      </strong>",
"      &mdash; Proteomic profiling is another investigational approach [",
"      <a class=\"abstract\" href=\"UTD.htm?11/13/11480/abstract/37-39\">",
"       37-39",
"      </a>",
"      ]. As an example, a study of 284 pregnant women determined a unique urine proteomic fingerprint that predicted preeclampsia of sufficient concern to warrant early delivery [",
"      <a class=\"abstract\" href=\"UTD.htm?11/13/11480/abstract/37\">",
"       37",
"      </a>",
"      ]. Nonrandom cleavage products of SERPINA1 and albumin could be observed several weeks in advance of clinical symptoms. This profile distinguished preeclampsia from other hypertensive and proteinuric disorders that occur during pregnancy. A nonreassuring urine profile had sensitivity and specificity of 85 and 87 percent, respectively, and positive and negative likelihood ratios of 6.7 and 0.2, respectively, which was more accurate than measurement of angiogenic factors for predicting the need for early delivery. Although promising, further investigation is needed.",
"     </li>",
"     <li>",
"      <strong>",
"       Genomic studies",
"      </strong>",
"      &mdash; The relationship between genetic polymorphisms and development of disease, including preeclampsia, is an active area of investigation. Studies of candidate genes have been on a small scale, have used varying methodologies, and have not yielded definitive results [",
"      <a class=\"abstract\" href=\"UTD.htm?11/13/11480/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     TESTS NOT USEFUL FOR PREDICTING PREECLAMPSIA",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Provocative biophysical tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aberrations in vascular responsiveness have formed the basis of several screening tests for the detection of pregnant women at risk for preeclampsia. None of these tests (angiotensin II challenge test [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11480/abstract/41,42\">",
"     41,42",
"    </a>",
"    ], roll-over test [supine pressor test] [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11480/abstract/42,43\">",
"     42,43",
"    </a>",
"    ], isometric exercise test [hand-grip test] [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11480/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]) are currently being used clinically because they are expensive, time-consuming, and, most importantly, unreliable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Serum uric acid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although hyperuricemia is commonly seen in women with preeclampsia, a systematic review of five studies concluded that measurement of serum uric acid concentration was not useful for predicting which women would develop preeclampsia [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11480/abstract/46\">",
"     46",
"    </a>",
"    ]. One study used a rise in serum uric acid concentration above baseline level as the criterion for a positive test result, while the other four studies used threshold values above 3.5 to 4",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (0.21 to 0.24",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    as the cut-off for a positive test. Sensitivities ranged from 0 to 56 percent and specificities ranged from 77 to 95 percent. The data were not pooled because of the methodological uncertainties and the clinical differences between studies [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11480/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similarly, a second systematic review concluded that serum uric acid measurement was not useful for predicting development of complications in women with preeclampsia [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11480/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Testing for inherited thrombophilias",
"    </span>",
"    &nbsp;&mdash;&nbsp;The weight of evidence, including data from prospective cohort studies [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11480/abstract/48,49\">",
"     48,49",
"    </a>",
"    ], indicates that inherited thrombophilias (such as Factor V Leiden mutation, prothrombin gene mutation, protein C or S deficiency, antithrombin deficiency) are not associated with preeclampsia; however, this is a controversial area discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/5/26714?source=see_link\">",
"     \"Inherited thrombophilias in pregnancy\"",
"    </a>",
"    .) Therefore, screening pregnant women for inherited thrombophilias is not useful for predicting those at high risk of developing the disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Testing for antiphospholipid antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antiphospholipid antibody syndrome is associated with development of severe early preeclampsia. However, screening the general obstetrical population for antiphospholipid antibodies (anticardiolipin antibody, lupus anticoagulant) is not useful. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/2/41000?source=see_link&amp;anchor=H10#H10\">",
"     \"Obstetrical manifestations of the antiphospholipid syndrome\", section on 'Preeclampsia/HELLP'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/2/41000?source=see_link&amp;anchor=H14#H14\">",
"     \"Obstetrical manifestations of the antiphospholipid syndrome\", section on 'When to evaluate for antiphospholipid antibodies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Testing maternal serum analytes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maternal serum analyte testing is an important component of Down syndrome screening programs. Increasing evidence suggests that unexplained abnormal maternal serum analyte concentrations in the first and second trimesters are also predictive of adverse pregnancy outcomes, including preeclampsia. However, this association is not sufficiently strong to warrant changes in routine prenatal care. Thus, maternal serum analyte testing for the sole purpose of prediction of preeclampsia is not recommended. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/57/18329?source=see_link&amp;anchor=H23#H23\">",
"     \"Pregnancy outcomes predicted by serum markers assayed in Down syndrome screening\", section on 'Preeclampsia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other biomarkers under investigation are asymmetric dimethylarginine and placental protein 13 [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11480/abstract/50-52\">",
"     50-52",
"    </a>",
"    ]. Placental protein 13 is specific to the placenta and involved implantation and placental vascular development.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     PREGNANCY MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since there are no clinically available tests that distinguish women who will develop preeclampsia from those who will not, all pregnant women are assessed for and educated about the signs and symptoms of the disease. As discussed above, early diagnosis and prompt and appropriate management (eg, antenatal corticosteroids for fetal lung maturation, treatment of severe hypertension, early delivery) may improve maternal outcome, and possibly perinatal outcome, as well.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Blood pressure and proteinuria monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnant women should be evaluated for signs and symptoms of preeclampsia at each prenatal visit after 20 weeks of gestation. Measurement of blood pressure and urine protein at regular intervals in the late second and third trimesters is critical for timely diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27978?source=see_link\">",
"     \"Preeclampsia: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although blood pressure should be measured at each prenatal visit to establish a baseline, detect subsequent changes, and confirm a diagnosis of preeclampsia, a mild elevation in systolic, diastolic, or mean arterial blood pressure in the second trimester is not useful as a screening test [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11480/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. A rising blood pressure is usually the first sign of developing preeclampsia, although it is not specific, as many women with an increase in blood pressure do not go on to develop the disease. A repeat examination in one to three days is recommended for women who do not meet criteria for establishing the diagnosis. Progression to preeclampsia can occur quickly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Patient education",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to information about the usual pregnancy concerns (decreased fetal movement, vaginal bleeding or leaking of fluid, preterm contractions), pregnant women should be educated to immediately report possible signs of preeclampsia that may occur between office visits, such as persistent or severe headache, visual changes (especially flashes of light or blurred vision), right upper quadrant or epigastric pain,",
"    <span class=\"nowrap\">",
"     nausea/vomiting,",
"    </span>",
"    sudden large weight gain, or facial or hand edema.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Women at high risk of developing preeclampsia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women at high risk of developing preeclampsia (",
"    <a class=\"graphic graphic_table graphicRef61266 \" href=\"UTD.htm?43/39/44667\">",
"     table 2",
"    </a>",
"    ) should be seen prior to conception to identify potentially modifiable risk factors. For example, natural weight loss in obese patients reduces insulin resistance and thus should reduce risk of preeclampsia, although this has not been evaluated in prospective studies. It has been shown that the incidence of preeclampsia in women who have undergone bariatric surgery falls to that of the general obstetrical population. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/18/27945?source=see_link&amp;anchor=H10#H10\">",
"     \"Fertility and pregnancy after bariatric surgery\", section on 'Preeclampsia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    High risk women should also be seen in early pregnancy to establish an accurate gestational age, baseline blood pressure, and baseline laboratory values, including platelet count, creatinine concentration, liver function tests, and urinary protein-to-creatinine ratio. This is helpful later in gestation in the differential diagnosis of fetal growth restriction and in distinguishing preeclampsia from underlying disorders associated with similar clinical and laboratory findings. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27978?source=see_link\">",
"     \"Preeclampsia: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We suggest more frequent monitoring of these women for signs and symptoms of severe hypertension or preeclampsia than that recommended for normal pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11480/abstract/55\">",
"     55",
"    </a>",
"    ]. This monitoring may include more frequent prenatal visits, home blood pressure monitoring, and serial ultrasound evaluation of fetal growth and amniotic fluid volume.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Multiple risk factors for development of preeclampsia have been described (",
"      <a class=\"graphic graphic_table graphicRef61266 \" href=\"UTD.htm?43/39/44667\">",
"       table 2",
"      </a>",
"      ). However, most of these risk factors are not highly predictive of the disorder, nor are they modifiable. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Prediction of preeclampsia based on risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are no clinically available tests that perform well in distinguishing women who will develop preeclampsia from those who will not. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Tests under investigation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Measurement of angiogenic factors (VEGF, PlGF, sFlt-1, sEng) in blood or urine is the most promising approach for predicting preeclampsia; however, these tests are investigational and are not available for clinical use at present. The ratio of sFlt-1:VEGF (or sFlt-1:PlGF), rather than absolute levels of these factors, appears to be most useful. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Tests under investigation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All pregnant women should be assessed for and educated about the signs and symptoms of the disease. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Pregnancy management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11480/abstract/1\">",
"      Levine RJ, Lindheimer MD. First-trimester prediction of early preeclampsia: a possibility at last! Hypertension 2009; 53:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11480/abstract/2\">",
"      Angeli F, Angeli E, Reboldi G, Verdecchia P. Hypertensive disorders during pregnancy: clinical applicability of risk prediction models. J Hypertens 2011; 29:2320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11480/abstract/3\">",
"      Myatt L, Clifton RG, Roberts JM, et al. First-trimester prediction of preeclampsia in nulliparous women at low risk. Obstet Gynecol 2012; 119:1234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11480/abstract/4\">",
"      Milne F, Redman C, Walker J, et al. The pre-eclampsia community guideline (PRECOG): how to screen for and detect onset of pre-eclampsia in the community. BMJ 2005; 330:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11480/abstract/5\">",
"      Caughey AB, Stotland NE, Washington AE, Escobar GJ. Maternal ethnicity, paternal ethnicity, and parental ethnic discordance: predictors of preeclampsia. Obstet Gynecol 2005; 106:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11480/abstract/6\">",
"      Cnossen JS, ter Riet G, Mol BW, et al. Are tests for predicting pre-eclampsia good enough to make screening viable? A review of reviews and critical appraisal. Acta Obstet Gynecol Scand 2009; 88:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11480/abstract/7\">",
"      Conde-Agudelo A, Villar J, Lindheimer M. World Health Organization systematic review of screening tests for preeclampsia. Obstet Gynecol 2004; 104:1367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11480/abstract/8\">",
"      Brice&ntilde;o-P&eacute;rez C, Brice&ntilde;o-Sanabria L, Vigil-De Gracia P. Prediction and prevention of preeclampsia. Hypertens Pregnancy 2009; 28:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11480/abstract/9\">",
"      Meads, CA, Cnossen, JS, Meher,S, et al. Methods of prediction and prevention of pre-eclampsia: systematic reviews of accuracy and effectiveness literature with economic modelling. Health Technol Assess 2008; 12:iii-iv.1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11480/abstract/10\">",
"      Cnossen JS, Morris RK, ter Riet G, et al. Use of uterine artery Doppler ultrasonography to predict pre-eclampsia and intrauterine growth restriction: a systematic review and bivariable meta-analysis. CMAJ 2008; 178:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11480/abstract/11\">",
"      Gigu&egrave;re Y, Charland M, Bujold E, et al. Combining biochemical and ultrasonographic markers in predicting preeclampsia: a systematic review. Clin Chem 2010; 56:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11480/abstract/12\">",
"      Levine RJ, Maynard SE, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004; 350:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11480/abstract/13\">",
"      Lam C, Lim KH, Karumanchi SA. Circulating angiogenic factors in the pathogenesis and prediction of preeclampsia. Hypertension 2005; 46:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11480/abstract/14\">",
"      Chaiworapongsa T, Romero R, Kim YM, et al. Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia. J Matern Fetal Neonatal Med 2005; 17:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11480/abstract/15\">",
"      Chaiworapongsa T, Romero R, Tarca AL, et al. A decrease in maternal plasma concentrations of sVEGFR-2 precedes the clinical diagnosis of preeclampsia. Am J Obstet Gynecol 2010; 202:550.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11480/abstract/16\">",
"      Maynard SE, Min JY, Merchan J, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11480/abstract/17\">",
"      Wolf M, Shah A, Lam C, et al. Circulating levels of the antiangiogenic marker sFLT-1 are increased in first versus second pregnancies. Am J Obstet Gynecol 2005; 193:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11480/abstract/18\">",
"      Venkatesha S, Toporsian M, Lam C, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006; 12:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11480/abstract/19\">",
"      Luft FC. Soluble endoglin (sEng) joins the soluble fms-like tyrosine kinase (sFlt) receptor as a pre-eclampsia molecule. Nephrol Dial Transplant 2006; 21:3052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11480/abstract/20\">",
"      AbdAlla S, Lother H, el Massiery A, Quitterer U. Increased AT(1) receptor heterodimers in preeclampsia mediate enhanced angiotensin II responsiveness. Nat Med 2001; 7:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11480/abstract/21\">",
"      Levine RJ, Lam C, Qian C, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006; 355:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11480/abstract/22\">",
"      Moore Simas TA, Crawford SL, Solitro MJ, et al. Angiogenic factors for the prediction of preeclampsia in high-risk women. Am J Obstet Gynecol 2007; 197:244.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11480/abstract/23\">",
"      Robinson CJ, Johnson DD. Soluble endoglin as a second-trimester marker for preeclampsia. Am J Obstet Gynecol 2007; 197:174.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11480/abstract/24\">",
"      Kleinrouweler CE, Wiegerinck MM, Ris-Stalpers C, et al. Accuracy of circulating placental growth factor, vascular endothelial growth factor, soluble fms-like tyrosine kinase 1 and soluble endoglin in the prediction of pre-eclampsia: a systematic review and meta-analysis. BJOG 2012; 119:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11480/abstract/25\">",
"      Levine RJ, Thadhani R, Qian C, et al. Urinary placental growth factor and risk of preeclampsia. JAMA 2005; 293:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11480/abstract/26\">",
"      Levine RJ, Hauth JC, Curet LB, et al. Trial of calcium to prevent preeclampsia. N Engl J Med 1997; 337:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11480/abstract/27\">",
"      Buhimschi CS, Baumbusch MA, Dulay AT, et al. The role of urinary soluble endoglin in the diagnosis of pre-eclampsia: comparison with soluble fms-like tyrosine kinase 1 to placental growth factor ratio. BJOG 2010; 117:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11480/abstract/28\">",
"      Buhimschi CS, Magloire L, Funai E, et al. Fractional excretion of angiogenic factors in women with severe preeclampsia. Obstet Gynecol 2006; 107:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11480/abstract/29\">",
"      Lim JH, Kim SY, Park SY, et al. Effective prediction of preeclampsia by a combined ratio of angiogenesis-related factors. Obstet Gynecol 2008; 111:1403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11480/abstract/30\">",
"      Kleinrouweler CE, Bossuyt PM, Thilaganathan B, et al. The added value of second trimester uterine artery Doppler to patient characteristics in the identification of nulliparous women at increased risk for pre-eclampsia: an individual patient data meta-analysis. Ultrasound Obstet Gynecol 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11480/abstract/31\">",
"      Chien PF, Arnott N, Gordon A, et al. How useful is uterine artery Doppler flow velocimetry in the prediction of pre-eclampsia, intrauterine growth retardation and perinatal death? An overview. BJOG 2000; 107:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11480/abstract/32\">",
"      Papageorghiou AT, Yu CK, Nicolaides KH. The role of uterine artery Doppler in predicting adverse pregnancy outcome. Best Pract Res Clin Obstet Gynaecol 2004; 18:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11480/abstract/33\">",
"      Yu CK, Smith GC, Papageorghiou AT, et al. An integrated model for the prediction of preeclampsia using maternal factors and uterine artery Doppler velocimetry in unselected low-risk women. Am J Obstet Gynecol 2005; 193:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11480/abstract/34\">",
"      Myatt L, Clifton RG, Roberts JM, et al. The utility of uterine artery Doppler velocimetry in prediction of preeclampsia in a low-risk population. Obstet Gynecol 2012; 120:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11480/abstract/35\">",
"      Stampalija T, Gyte GM, Alfirevic Z. Utero-placental Doppler ultrasound for improving pregnancy outcome. Cochrane Database Syst Rev 2010; :CD008363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11480/abstract/36\">",
"      Poon LC, Kametas NA, Maiz N, et al. First-trimester prediction of hypertensive disorders in pregnancy. Hypertension 2009; 53:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11480/abstract/37\">",
"      Buhimschi IA, Zhao G, Funai EF, et al. Proteomic profiling of urine identifies specific fragments of SERPINA1 and albumin as biomarkers of preeclampsia. Am J Obstet Gynecol 2008; 199:551.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11480/abstract/38\">",
"      Heitner JC, Koy C, Kreutzer M, et al. Differentiation of HELLP patients from healthy pregnant women by proteome analysis--on the way towards a clinical marker set. J Chromatogr B Analyt Technol Biomed Life Sci 2006; 840:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11480/abstract/39\">",
"      Watanabe H, Hamada H, Yamada N, et al. Proteome analysis reveals elevated serum levels of clusterin in patients with preeclampsia. Proteomics 2004; 4:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11480/abstract/40\">",
"      Zhong Y, Tuuli M, Odibo AO. First-trimester assessment of placenta function and the prediction of preeclampsia and intrauterine growth restriction. Prenat Diagn 2010; 30:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11480/abstract/41\">",
"      Gant NF, Daley GL, Chand S, et al. A study of angiotensin II pressor response throughout primigravid pregnancy. J Clin Invest 1973; 52:2682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11480/abstract/42\">",
"      Dekker GA, Makovitz JW, Wallenburg HC. Prediction of pregnancy-induced hypertensive disorders by angiotensin II sensitivity and supine pressor test. Br J Obstet Gynaecol 1990; 97:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11480/abstract/43\">",
"      Gant NF, Chand S, Worley RJ, et al. A clinical test useful for predicting the development of acute hypertension in pregnancy. Am J Obstet Gynecol 1974; 120:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11480/abstract/44\">",
"      Tomoda S, Kitanaka T, Ogita S, Hidaka A. Prediction of pregnancy-induced hypertension by isometric exercise. Asia Oceania J Obstet Gynaecol 1994; 20:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11480/abstract/45\">",
"      Baker PN, Johnson IR. The use of the hand-grip test for predicting pregnancy-induced hypertension. Eur J Obstet Gynecol Reprod Biol 1994; 56:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11480/abstract/46\">",
"      Cnossen JS, de Ruyter-Hanhij&auml;rvi H, van der Post JA, et al. Accuracy of serum uric acid determination in predicting pre-eclampsia: a systematic review. Acta Obstet Gynecol Scand 2006; 85:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11480/abstract/47\">",
"      Thangaratinam S, Ismail KM, Sharp S, et al. Accuracy of serum uric acid in predicting complications of pre-eclampsia: a systematic review. BJOG 2006; 113:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11480/abstract/48\">",
"      Dizon-Townson D, Miller C, Sibai B, et al. The relationship of the factor V Leiden mutation and pregnancy outcomes for mother and fetus. Obstet Gynecol 2005; 106:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11480/abstract/49\">",
"      Silver RM, Zhao Y, Spong CY, et al. Prothrombin gene G20210A mutation and obstetric complications. Obstet Gynecol 2010; 115:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11480/abstract/50\">",
"      Savvidou MD, Hingorani AD, Tsikas D, et al. Endothelial dysfunction and raised plasma concentrations of asymmetric dimethylarginine in pregnant women who subsequently develop pre-eclampsia. Lancet 2003; 361:1511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11480/abstract/51\">",
"      Chafetz I, Kuhnreich I, Sammar M, et al. First-trimester placental protein 13 screening for preeclampsia and intrauterine growth restriction. Am J Obstet Gynecol 2007; 197:35.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11480/abstract/52\">",
"      Speer PD, Powers RW, Frank MP, et al. Elevated asymmetric dimethylarginine concentrations precede clinical preeclampsia, but not pregnancies with small-for-gestational-age infants. Am J Obstet Gynecol 2008; 198:112.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11480/abstract/53\">",
"      Myatt L, Miodovnik M. Prediction of preeclampsia. Semin Perinatol 1999; 23:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11480/abstract/54\">",
"      Cnossen JS, Vollebregt KC, de Vrieze N, et al. Accuracy of mean arterial pressure and blood pressure measurements in predicting pre-eclampsia: systematic review and meta-analysis. BMJ 2008; 336:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11480/abstract/55\">",
"      Barton JR, Sibai BM. Prediction and prevention of recurrent preeclampsia. Obstet Gynecol 2008; 112:359.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6750 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-528937E1C1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_13_11480=[""].join("\n");
var outline_f11_13_11480=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PREDICTION OF PREECLAMPSIA BASED ON RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TESTS UNDER INVESTIGATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Limitations of available data",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Levels of angiogenic factors in blood and urine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4144786\">",
"      - Blood",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4144793\">",
"      - Urine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Ratio of angiogenic factors in blood and urine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Uterine artery Doppler velocimetry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Novel approaches",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      TESTS NOT USEFUL FOR PREDICTING PREECLAMPSIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Provocative biophysical tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Serum uric acid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Testing for inherited thrombophilias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Testing for antiphospholipid antibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Testing maternal serum analytes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      PREGNANCY MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Blood pressure and proteinuria monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Patient education",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Women at high risk of developing preeclampsia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/6750\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6750|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/31/4603\" title=\"table 1\">",
"      Criteria for preeclampsia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?43/39/44667\" title=\"table 2\">",
"      Risk factors for preeclampsia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/18/27945?source=related_link\">",
"      Fertility and pregnancy after bariatric surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/5/26714?source=related_link\">",
"      Inherited thrombophilias in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/2/41000?source=related_link\">",
"      Obstetrical manifestations of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/61/34777?source=related_link\">",
"      Pathogenesis of preeclampsia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27978?source=related_link\">",
"      Preeclampsia: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/23/21882?source=related_link\">",
"      Preeclampsia: Management and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/57/18329?source=related_link\">",
"      Pregnancy outcomes predicted by serum markers assayed in Down syndrome screening",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41609?source=related_link\">",
"      Prevention of preeclampsia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_13_11481="Clinical manifestations and diagnosis of depression";
var content_f11_13_11481=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and diagnosis of depression",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/13/11481/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/13/11481/contributors\">",
"     Jeffrey M Lyness, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/13/11481/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/13/11481/contributors\">",
"     Peter P Roy-Byrne, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/13/11481/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/13/11481/contributors\">",
"     David Solomon, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/13/11481/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 19, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depression is a major public health problem and a leading predictor of functional disability and mortality. The annual economic consequences of depression have been estimated at 83 billion dollars in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11481/abstract/1\">",
"     1",
"    </a>",
"    ] and 118 billion euro in Europe [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11481/abstract/2\">",
"     2",
"    </a>",
"    ]. Optimal depression treatment improves outcomes for most patients.",
"   </p>",
"   <p>",
"    Although most adults with clinically significant depression never see a mental health professional, they often see a primary care physician. Yet substantial numbers of depressed primary care patients remain undiagnosed or under-treated, reflecting attitudes and practices of physicians, patients, families, and health care systems. A systematic review of 36 studies found that non-psychiatric physicians missed the diagnosis of depression in over one half of patients seen [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11481/abstract/3\">",
"     3",
"    </a>",
"    ], although these findings should be interpreted with recognition of the difference between primary care and psychiatric practice in the severity of depression, the complexity of diagnosing and treating depression in the context of other chronic medical illness, and the primary care approach to diagnosis over several office visits.",
"   </p>",
"   <p>",
"    This topic will focus on the clinical features and diagnosis of depression. The epidemiology, pathogenesis, treatment, and prognosis of depression in adults and elderly patients are discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/38/37481?source=see_link\">",
"       \"Unipolar depression in adults: Epidemiology, pathogenesis, and neurobiology\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=see_link\">",
"       \"Initial treatment of depression in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27609?source=see_link\">",
"       \"Treatment of resistant depression in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/37/39514?source=see_link\">",
"       \"Diagnosis and management of late-life depression\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/19/38201?source=see_link\">",
"       \"Unipolar depression in adults: Prognosis and course of illness\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important to recognize the potential for confusion engendered by multiple uses of the term 'depression.' Depression may refer to:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A mood state, which may be normal or part of a psychopathological syndrome.",
"     </li>",
"     <li>",
"      A syndrome, which is a constellation of symptoms and signs (eg, a major depressive syndrome).",
"     </li>",
"     <li>",
"      A specific disorder, identifying a distinct clinical condition. For example, major depressive syndrome may be the consequence of one of several disorders: idiopathic ('primary') major depressive disorder, 'secondary' major depression due to a general medical condition or substance use disorder, bipolar I or II disorder, or other entities discussed below.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depressive syndromes are defined in DSM-IV-TR [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11481/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Major depression",
"    </span>",
"    &nbsp;&mdash;&nbsp;A major depressive syndrome or episode manifests with five or more of the following symptoms, present most of the day nearly every day for a minimum of two consecutive weeks. At least one symptom is either depressed mood or loss of interest or pleasure.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Depressed mood",
"     </li>",
"     <li>",
"      Loss of interest or pleasure in most or all activities",
"     </li>",
"     <li>",
"      Insomnia or hypersomnia",
"     </li>",
"     <li>",
"      Change in appetite or weight",
"     </li>",
"     <li>",
"      Psychomotor retardation or agitation",
"     </li>",
"     <li>",
"      Low energy",
"     </li>",
"     <li>",
"      Poor concentration",
"     </li>",
"     <li>",
"      Thoughts of worthlessness or guilt",
"     </li>",
"     <li>",
"      Recurrent thoughts about death or suicide",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Conceptually these symptoms may be grouped as disturbances in:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Emotions (depressed mood, loss of interests or pleasure)",
"     </li>",
"     <li>",
"      Ideation (worthlessness or guilt, death or suicide)",
"     </li>",
"     <li>",
"      Neurovegetative or somatic symptoms (sleep, appetite or weight, energy, psychomotor, concentration)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Eight of these symptoms (all but depressed mood) may be more readily recalled using the mnemonic \"SIG: E CAPS\" (ie, \"prescribe energy capsules\"): Sleep, Interest, Guilt, Energy, Concentration, Appetite, Psychomotor, Suicide.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Dysthymic disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dysthymic disorder is marked by depressed mood for at least two years. Depression is present for most of the day, for more days than not. The depressed mood is accompanied by two or more of the following symptoms:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Decreased or increased appetite",
"     </li>",
"     <li>",
"      Insomnia or hypersomnia",
"     </li>",
"     <li>",
"      Low energy",
"     </li>",
"     <li>",
"      Poor self esteem",
"     </li>",
"     <li>",
"      Poor concentration",
"     </li>",
"     <li>",
"      Hopelessness",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, symptoms are not as numerous as in major depression. Symptom free periods during the course of dysthymia can occur, but may not exceed two months during the two year (or longer) timeframe. A major depressive episode may not occur during the first two years of dysthymic disorder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H260614653\">",
"    <span class=\"h2\">",
"     Adjustment disorder with depressed mood",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adjustment disorder with depressed mood is a condition that occurs in response to an identifiable psychosocial stressor. The stressor may be a single event or there may be multiple stressors, and a stressor may be recurrent or continuous. Adjustment disorder with depressed mood is not classified as a mood disorder. Rather, adjustment disorder describes patients suffering clinically significant symptoms that do not meet criteria for a more specific psychiatric disorder such as major depression or dysthymic disorder. The criteria for adjustment disorder with depressed mood are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Depressed mood or functional impairment that occurs in response to an identifiable stressor within three months of onset of the stressor",
"     </li>",
"     <li>",
"      Symptoms are clinically significant as evidenced by at least one of the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Depressed mood exceeds what would be expected given the nature of the stressor",
"     </li>",
"     <li>",
"      Social or occupational functioning is significantly impaired",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The syndrome does not meet criteria for another psychiatric disorder (eg, major depression). &nbsp;",
"     </li>",
"     <li>",
"      The syndrome does not represent an exacerbation of a preexisting psychiatric disorder",
"     </li>",
"     <li>",
"      The syndrome does not represent bereavement",
"     </li>",
"     <li>",
"      After the stressor has ended, the syndrome resolves within six months",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Major depression and other mood disorders often occur in the context of psychosocial stressors, and the diagnosis of adjustment disorder with depressed mood is superseded by a mood disorder. The clinician distinguishes a mood disorder from adjustment disorder not by noting whether a stressor is present, but by determining whether the patient&rsquo;s symptoms are sufficient in number, severity, and duration to meet diagnostic criteria for major depression or another mood disorder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Minor depression",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis and clinical features of minor depression are discussed separately (as are the management and treatment). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/26/26025?source=see_link\">",
"     \"Unipolar minor depression in adults: Epidemiology, clinical presentation, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/12/35015?source=see_link\">",
"     \"Unipolar minor depression in adults: Management and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The DSM-IV-TR criteria for depressive disorders, as for other mental disorders, require that the depressive episode cause significant distress or dysfunction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Emotional symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The nature of the \"depressed mood\" may vary. Some patients communicate intense sadness and emotional distress, while others report a sense of emotional numbness (\"blahs\") and exhibit a \"flattened\" affect on examination. Patients may present with prominent anxiety or irritability; although not specific for depression, these symptoms should be recognized as part of a depressive episode if they occur in the context and timeframe of other features of depression.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Neurovegetative symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some neurovegetative symptoms of depression, such as loss of energy, occur only in one 'direction'. Others, including changes in sleep, appetite, or weight, are potentially bidirectional: insomnia and anorexia with weight loss are most common in depression, but some patients experience 'reverse signs' of hypersomnia or hyperphagia with weight gain.",
"   </p>",
"   <p>",
"    Such reverse signs, associated with depressive episodes, are more common in bipolar disorder, but may occur in unipolar major depression.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86452216\">",
"    <span class=\"h2\">",
"     Gender differences",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical presentation of depression may vary between women and men. Depressed women may be more likely to report neurovegetative symptoms and other physical symptoms (eg, myalgias), as well as emotional and psychosocial symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11481/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. By contrast, men often present with irritability [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11481/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Subtypes of major depression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several subtypes of major depression have implications for treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Major depression with atypical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combination of reverse signs with leaden paralysis or interpersonal rejection sensitivity is characteristic of the syndrome known as \"major depression with atypical features\" or \"atypical depression\" [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11481/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Seasonal affective disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients have recurrent major depressive episodes in a seasonal pattern (\"seasonal affective disorder\" or \"SAD\"), which may respond to light therapy in addition to, or instead of, psychotherapy or medications (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/25/22936?source=see_link\">",
"     \"Seasonal affective disorder\"",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11481/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Major depression with melancholic features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe depression marked by profoundly depressed and non-reactive mood (ie, mood that does not brighten even temporarily in response to positive circumstances or stimuli), together with severe neurovegetative symptoms (eg, severe early morning awakening, substantial weight loss) is termed \"major depression with melancholic features.\" Patients with melancholic major depression often also have a disturbance of thought processes known as ruminative thinking, ie, dwelling on negativistic themes to the exclusion of other thought content.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Major depression with psychotic features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some severely depressed patients develop psychotic symptoms and are diagnosed with \"major depression with psychotic features\" (often referred to as \"psychotic depression\"). The most common psychotic symptoms in psychotic depression are delusions and hallucinations. Psychotic depression is discussed separately (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/15/5368?source=see_link\">",
"     \"Unipolar major depression with psychotic features: Epidemiology, clinical features, assessment, and diagnosis\"",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Minor depression",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical features and diagnosis of minor depression are discussed separately (as are the management and treatment). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/26/26025?source=see_link\">",
"     \"Unipolar minor depression in adults: Epidemiology, clinical presentation, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/12/35015?source=see_link\">",
"     \"Unipolar minor depression in adults: Management and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis for all psychiatric disorders requires consideration of diagnostic possibilities from two perspectives: the psychiatric syndrome and the underlying etiology.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Syndromic",
"    </span>",
"    &nbsp;&mdash;&nbsp;The syndromic perspective matches the pattern of the patient's symptoms and signs with established, syndromically-defined disorders: eg, major depressive syndrome in the course of major depressive disorder (",
"    <a class=\"graphic graphic_algorithm graphicRef74999 \" href=\"UTD.htm?20/3/20543\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    When subsyndromal depressive symptoms occur in response to an identifiable psychosocial stressor, the patient may be diagnosed with an 'adjustment disorder with depressed mood.' If the depressive symptoms meet syndromic criteria for major depression, however, major depression should be diagnosed, and not an adjustment disorder, even if the symptoms are attributable to a stressor. Patients diagnosed with adjustment disorder may subsequently develop major depression; one study found this occurred in 13 percent of patients with adjustment disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11481/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If the stressor was the loss of a loved one, and the impact on the patient's functional status is in keeping with expected cultural norms, the patient's condition may be described as normal bereavement.",
"   </p>",
"   <p>",
"    Subsyndromal depressive symptoms may be seen in the course of many other psychiatric disorders (see",
"    <a class=\"local\" href=\"#H19\">",
"     'Comorbidities'",
"    </a>",
"    below). Apathy in the absence of a full depressive syndrome may be seen with cognitive disorders (eg, delirium, dementia) or various other neuropsychiatric syndromes (eg, frontal lobe dysfunction from a wide range of neurological causes).",
"   </p>",
"   <p>",
"    Idiopathic depressive episodes also may be part of the course of other mental disorders, including bipolar disorder and schizoaffective disorder. In bipolar disorder, the illness course includes episodes of mania (bipolar I) or hypomania (bipolar II) as well as depression. The course of schizoaffective disorder includes episodes of psychosis (without a concurrent mood syndrome) as well as episodes of mania or depression with psychotic features (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/11/19639?source=see_link\">",
"     \"Bipolar disorder in adults: Epidemiology and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/58/28583?source=see_link\">",
"     \"Overview of psychosis\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Etiologic",
"    </span>",
"    &nbsp;&mdash;&nbsp;The etiologic perspective requires considering whether the depressive episode is caused by a specific physical agent or condition, or represents a unipolar primary (idiopathic) depressive disorder. Depressive syndromes may be caused by a wide range of systemic or neurologic medical illnesses (mood disorder due to a general medical condition), or substance intoxication or withdrawal (substance-induced mood disorder) (",
"    <a class=\"graphic graphic_table graphicRef52373 \" href=\"UTD.htm?0/13/220\">",
"     table 1",
"    </a>",
"    ); these are often referred to as secondary depression.",
"   </p>",
"   <p>",
"    Substance-induced depressions can be due to drugs used or abused for recreational purposes, or to medications prescribed in the treatment of a variety of disorders. Alcohol, sedative-hypnotics, and withdrawal from stimulants are the most common recreational drugs underlying secondary depression. Prescription drugs that may precipitate depression include antihypertensive agents (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/15/28918?source=see_link\">",
"     methyldopa",
"    </a>",
"    ); dopamine-blocking agents including first-generation antipsychotics (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    ) and GI drugs such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/28/22984?source=see_link\">",
"     prochlorperazine",
"    </a>",
"    ; glucocorticoids; and interferon-alpha.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     COMORBIDITIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Major depression may exist as a sole diagnosis, but is commonly concurrent with other psychiatric or medical disorders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Psychiatric comorbidity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most important psychiatric comorbidities are [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11481/abstract/12\">",
"     12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Anxiety disorders (particularly panic disorder, obsessive-compulsive disorder, and posttraumatic stress disorder)",
"     </li>",
"     <li>",
"      Cognitive disorders (specifically dementia)",
"     </li>",
"     <li>",
"      Eating disorders",
"     </li>",
"     <li>",
"      Somatoform disorders",
"     </li>",
"     <li>",
"      Personality disorders",
"     </li>",
"     <li>",
"      Sleep disorders (eg, obstructive sleep apnea)",
"     </li>",
"     <li>",
"      Substance use disorders (the combination of substance use disorders with a primary psychiatric disorder is sometimes termed \"dual diagnosis\").",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Anxiety is a common manifestation of depressive disorders, and a part of the spectrum of mood disorders. Generalized anxiety that is only present during periods of active depression does not warrant a separate diagnosis of anxiety disorder, unless other features of the anxiety (panic disorder, obsessive-compulsive disorder, and posttraumatic stress disorder) are present. The prognosis for depression with any comorbidity is poorer than for depression occurring in isolation.",
"   </p>",
"   <p>",
"    Treatment strategies will differ depending on the nature and temporal relationship of the comorbidity. For example, one may target initial treatment primarily at depression in a patient who develops new-onset obsessions and compulsions in the context of a major depressive episode. Whether patients with concurrent alcohol abuse and major depression should be treated for depression prior to addressing the substance abuse is somewhat controversial, with a trend favoring treatment for depression when the diagnosis of major depression is established, regardless of ongoing substance use [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11481/abstract/13\">",
"     13",
"    </a>",
"    ] (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41847?source=see_link\">",
"     \"Psychosocial treatment of alcohol abuse and dependence\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/48/19209?source=see_link\">",
"     \"Pharmacotherapy for alcohol abuse and dependence\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Medical comorbidity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rates of depression are increased in patients with most major chronic medical and neurological disorders, as well as with many subacute and acute medical conditions and their treatments [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11481/abstract/14\">",
"     14",
"    </a>",
"    ]. Rates of depression may be particularly high in diseases of the central nervous system (eg, stroke, traumatic brain injury, Parkinson disease) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11481/abstract/15-17\">",
"     15-17",
"    </a>",
"    ], cardiovascular disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11481/abstract/18,19\">",
"     18,19",
"    </a>",
"    ], cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11481/abstract/20\">",
"     20",
"    </a>",
"    ], and conditions involving immune and inflammatory mechanisms (eg, systemic lupus erythematosus [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11481/abstract/21\">",
"     21",
"    </a>",
"    ]). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/22/31080?source=see_link\">",
"     \"Diagnosis of psychiatric and psychologic disorders in patients with cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/55/16250?source=see_link\">",
"     \"Psychosocial and other social factors in acute myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/12/17610?source=see_link\">",
"     \"Medical complications of stroke\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The relationship between depression and chronic disease is reciprocal, with the risk of chronic medical conditions such as diabetes and coronary artery disease increased in patients with depression [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11481/abstract/14\">",
"     14",
"    </a>",
"    ]. The depression-medical comorbidity interface is not specific to any disease type or organ system. In addition to increasing risk for disease, depression worsens the outcome of comorbid physical conditions, including the risk of medical death. Comorbid depression in older patients with diabetes increased risk for all-cause mortality by 36 to 38 percent over a two year period [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11481/abstract/22\">",
"     22",
"    </a>",
"    ]. Increased mortality may relate to decreased adherence to treatment recommendations [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11481/abstract/23\">",
"     23",
"    </a>",
"    ] or possibly to direct effects of the depressed state on autonomic tone, platelet aggregation, or immune and inflammatory responses [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11481/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As with psychiatric comorbidities, the prognosis of depression is worsened by the presence of significant medical comorbidity. Even in the context of severe physical disease and disability, the potential efficacy of depression treatments, with resulting improvements in self-rated health and functional status, must be recognized and conveyed to patients and families.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SCREENING FOR DEPRESSION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Screening tools",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several self-report depression screening instruments available for use in primary care settings, including the Center for Epidemiologic Studies Depression Scale (CES-D) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11481/abstract/25\">",
"     25",
"    </a>",
"    ] and the Geriatric Depression Scale (GDS) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11481/abstract/26\">",
"     26",
"    </a>",
"    ]. Operating characteristics of these instruments do not differ substantially from each other, although vary considerably across studies, with sensitivities ranging from 50 to 97 percent (median 85 percent) and specificities from 51 to 98 percent (median 74 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11481/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These screening scales typically have approximately 15 to 30 questions eliciting symptoms of depression, although shorter versions of some scales have demonstrated similar utility. Screening instruments must be followed up with a clinical interview to establish the diagnosis of depression.",
"   </p>",
"   <p>",
"    Shorter versions of screening tools (ranging from two to nine questions) are available and facilitate screening. Sensitivity and specificities of shorter tools are slightly lower than longer screening questionnaires [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11481/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Five-item Geriatric Depression Scale",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 5-item version of the GDS has been validated in older adults [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11481/abstract/29\">",
"     29",
"    </a>",
"    ]. Its parent scale, despite the name, also has been validated in younger adults [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11481/abstract/30\">",
"     30",
"    </a>",
"    ]. These five items are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Are you basically satisfied with your life?",
"     </li>",
"     <li>",
"      Do you often get bored?",
"     </li>",
"     <li>",
"      Do you often feel helpless?",
"     </li>",
"     <li>",
"      Do you prefer to stay at home rather than going out and doing new things?",
"     </li>",
"     <li>",
"      Do you feel pretty worthless the way you are now?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A single point is given for a 'no' response to the first item and a 'yes' response to each of the other four items. A score of 2 points or greater is considered a positive screen for depression.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Two-item screening tool",
"    </span>",
"    &nbsp;&mdash;&nbsp;Even shorter screens may offer similar utility, including the single question, \"Are you depressed?\" [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11481/abstract/31,32\">",
"     31,32",
"    </a>",
"    ] or two questions assessing depressed mood and anhedonia [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11481/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      During the past month, have you felt down, depressed or hopeless?",
"     </li>",
"     <li>",
"      During the past month, have you felt little interest or pleasure in doing things?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A 'yes' response to either question is considered a positive screen.",
"   </p>",
"   <p>",
"    The PHQ-2 is a similar screening tool, which asks about the frequency of depressed mood and anhedonia over the past two weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11481/abstract/35\">",
"     35",
"    </a>",
"    ]. Sensitivity for this tool was good (0.83 and 0.87) in two studies in general medical outpatients, but it did not perform as well in a population of cardiology patients [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11481/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Patient Health Questionnaire - Nine Item (PHQ-9)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Patient Health Questionnaire &ndash; Nine Item (PHQ-9) is a 9-item self-report instrument that assesses each symptom of DSM-IV-TR major depression, and is easy to use, reliable, and valid in primary care settings (",
"    <a class=\"graphic graphic_table graphicRef59307 \" href=\"UTD.htm?14/12/14541\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11481/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. The PHQ-9 establishes the clinical diagnosis of depression, and does not require further confirmation. This allows the clinician more time to be spent on patient education and negotiation of the treatment plan. The PHQ-9 sum score also can be used to track the severity of patient symptoms over time [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11481/abstract/38\">",
"     38",
"    </a>",
"    ], which is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/40/4745?source=see_link&amp;anchor=H100014092#H100014092\">",
"     \"Using scales to monitor symptoms and treatment of depression (measurement based care)\", section on 'Patient Health Questionnaire - Nine Item'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Beck Depression Inventory for Primary Care",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Beck Depression Inventory for Primary Care (BDI-PC) is a 7-item scale [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11481/abstract/39\">",
"     39",
"    </a>",
"    ] adapted from the extensively validated 21-item Beck Depression Inventory [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11481/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. In primary care outpatients, the BDI-PC with a cut-off of 4 points had a 97 percent sensitivity and 99 percent specificity for identifying major depression [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11481/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Effectiveness of depression screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Concerns have been raised about the cost-effectiveness of screening, and the relatively low positive predictive value of screening tools (&lt;50 percent), given the depression prevalence &lt;10 percent in the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11481/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. A 2005 meta-analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11481/abstract/45\">",
"     45",
"    </a>",
"    ] and 2008 update [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11481/abstract/46\">",
"     46",
"    </a>",
"    ] found substantial evidence that",
"    <span class=\"nowrap\">",
"     screening/case-finding",
"    </span>",
"    interventions alone have \"minimal impact\" on the detection, management, or outcome of depression by clinicians in non-mental health settings (eg, primary care or general hospitals). The US Preventive Services Task Force recommends screening adults for depression only in practices that have available clinical care management support staff to assure accuracy in diagnosis, and to provide selective consultation, effective treatment, and follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11481/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Large scale randomized trials are needed to determine whether screening combined with other practice-based interventions will improve outcomes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     MAKING THE DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary depressive disorders are defined by syndrome criteria so diagnosis depends on clinical history and examination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     History and mental status examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;History is the most important component of the evaluation. The history should be obtained from the patient and may often also involve information from others such as family members or other treatment providers. Issues of patient confidentiality and consent must be recognized when sources other than the patient are considered. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/38/18025?source=see_link&amp;anchor=H4#H4\">",
"     \"Family and couples therapy for treating depressed adults\", section on 'Assessment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Psychiatric symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The interview should:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Establish the presence or absence of each of the cardinal nine symptoms of depression, as well as other associated symptoms (see",
"      <a class=\"local\" href=\"#H3\">",
"       'Diagnosis'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Determine the chronology of the depressive symptoms.",
"     </li>",
"     <li>",
"      Determine the impact of the depressive episode on functional status.",
"     </li>",
"     <li>",
"      Elicit alleviating or aggravating factors, including stressful life events and social or occupational circumstances.",
"     </li>",
"     <li>",
"      Include a mental status examination. This examination supplements the history by observing the presence of depressive signs (eg, alterations in speech, psychomotor activity, mood and affect, ruminative thought processes, and negativistic or suicidal thought content).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Medical history",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the potential for general medical conditions (spanning all organ systems) and drugs to cause or contribute to depressive episodes, it is important to carefully assess:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Current and past medical history",
"     </li>",
"     <li>",
"      Medication use",
"     </li>",
"     <li>",
"      Review of systems.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Suicide risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;All depressed patients must be queried specifically about suicidal ideation. Any positive or equivocal response should be followed up immediately with the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ask about the specific nature of the ideation, intent, plans, and actions.",
"     </li>",
"     <li>",
"      Assess risk factors for suicide: other psychiatric disorders, medical illnesses, prior history of suicide attempts, and family history of attempted suicide or death by suicide. Demographic risks, including older age, male gender, age-specific race risks (eg, older white males, young adult black males), marital status (eg, widowed or separated), and living alone, should also be considered.",
"     </li>",
"     <li>",
"      Develop a safe plan for further evaluation and treatment, which depending on the level of risk may range from continued primary follow-up alone to outpatient or emergency room psychiatric evaluation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Comorbid psychiatric disorders and family history",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the importance of psychiatric comorbidities, it is essential to ask about the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anxiety symptoms",
"     </li>",
"     <li>",
"      Alcohol and other substance use",
"     </li>",
"     <li>",
"      Cognitive symptoms and functioning, especially In the elderly and in younger persons at risk because of",
"      <span class=\"nowrap\">",
"       medical/neurological",
"      </span>",
"      illness",
"     </li>",
"     <li>",
"      Prior history of hypomanic, manic, and psychotic episodes. A diagnosis of bipolar or schizoaffective disorder requires psychiatric consultation and different management than that for unipolar depressions.",
"     </li>",
"     <li>",
"      Family history of mood or other psychiatric disorders, which may confer increased risk for particular disorders or suicide in the patient.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Comorbid medical conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The likelihood that a clinically occult medical illness is causing or contributing to a depressive episode is increased in the following circumstances:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Severe new-onset depression, including melancholia and psychotic depression",
"     </li>",
"     <li>",
"      New-onset depression in an older adult",
"     </li>",
"     <li>",
"      New-onset or recurrent depression that is not readily understood in the context of the patient's psychosocial stressors and circumstances",
"     </li>",
"     <li>",
"      Depression that has not responded to treatment attempts",
"     </li>",
"     <li>",
"      Depression with significant coexisting cognitive impairment, anxiety, substance use disorder, or other comorbid psychopathology",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients in any of these categories, and for new-onset depression in younger adults with comorbid severe chronic or acute medical illness, evaluation should include a screening general physical exam, including neurological exam.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h3\">",
"     Laboratory evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is scant empirical cost-benefit evidence to inform the laboratory work-up for depression. For patients at higher risk of underlying medical illness, as outlined above, consideration should be given to assessing the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complete blood count",
"     </li>",
"     <li>",
"      Serum electrolytes and glucose",
"     </li>",
"     <li>",
"      BUN and creatinine",
"     </li>",
"     <li>",
"      Hepatocellular enzymes",
"     </li>",
"     <li>",
"      TSH",
"     </li>",
"     <li>",
"      RPR (especially in older or patients otherwise at-risk for neurosyphilis)",
"     </li>",
"     <li>",
"      Serum B12 and folate",
"     </li>",
"     <li>",
"      Urinalysis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other tests, to be considered based on individual circumstances, might include an EKG if dysrhythmia is suspected as a source of possible embolic cerebral infarct, and neuroimaging (MRI preferred) for clinically occult vascular or mass lesions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h1\">",
"     WHEN TO REFER",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision to refer patients to a mental health specialist will depend on many factors: the primary care provider's own level of expertise and confidence in assessing and treating depression, the availability of mental health specialty resources,",
"    <span class=\"nowrap\">",
"     patient/family",
"    </span>",
"    preference, and patient response to initial therapy. In general, the following clinical factors should lead to psychiatric referral sooner rather than later:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Severe depression that is endangering the life of the patient (ie, suicidality or inability to care for self) or others (aggressivity or inability to care for dependent others).",
"     </li>",
"     <li>",
"      Depression that has failed to respond to initial treatment trials, whether due to patient adherence, perceived side effects, or treatment-refractoriness.",
"     </li>",
"     <li>",
"      Desire to treat with psychotherapy, light therapy, electroconvulsive therapy, or other modalities requiring specialty expertise.",
"     </li>",
"     <li>",
"      Psychotic depression.",
"     </li>",
"     <li>",
"      Depression that is part of the course of bipolar disorder, schizoaffective disorder, or another major psychiatric illness.",
"     </li>",
"     <li>",
"      Depression whose presentation or management is complicated by significant psychiatric comorbidity.",
"     </li>",
"     <li>",
"      Patients for whom the diagnosis of depression (or its comorbidities) is uncertain.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/57/12179?source=see_link\">",
"       \"Patient information: Depression (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?19/41/20116?source=see_link\">",
"       \"Patient information: Depression in adults (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?13/6/13413?source=see_link\">",
"       \"Patient information: Depression in adolescents (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Major depression, as defined by DSM-IV-TR, requires the presence of a minimum of five of nine symptoms, including a depressed mood or loss of interest, most of the day nearly every day for a minimum of two consecutive weeks. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Major depression'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Dysthymic disorder is diagnosed in patients with two or more depressive symptoms that are present most of the time for a period lasting at least two years. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Dysthymic disorder'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Minor depression presents with fewer symptoms than major depression. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/26/26025?source=see_link\">",
"       \"Unipolar minor depression in adults: Epidemiology, clinical presentation, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Subtypes of major depression include atypical depression, seasonal affective disorder, psychotic depression, and depression with melancholic features. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Subtypes of major depression'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of a depressive episode includes determining the psychiatric syndrome and determining if the etiology is idiopathic or related to an underlying systemic or neurologic condition, substance use, or prescription medication side effect. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several screening tools have been developed to identify patients with depression in the primary care setting. All, except the PHQ-9, require follow-up interview to establish the diagnosis of depression. However, screening for depression has not been consistently demonstrated to improve management or outcome of depression. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Screening for depression'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of depression is largely based on patient history and mental status examination. Assessment should include evaluation for suicide risk. History should also include a comprehensive medical history, exploration of comorbid psychiatric disorders including substance use, and family history. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Making the diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although there is no evidence to support routine laboratory testing in the diagnosis of depression, CBC, a basic chemistry profile, liver function tests, TSH, RPR, B12 and folate levels may be helpful when underlying medical conditions are suspected. (See",
"      <a class=\"local\" href=\"#H35\">",
"       'Comorbid medical conditions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Referral to a mental health specialist is indicated for patients with severe depression, depression unresponsive to initial treatment, psychotic depression or depression that is part of bipolar disorder, schizoaffective disorder or other major psychiatric illness. (See",
"      <a class=\"local\" href=\"#H37\">",
"       'When to refer'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11481/abstract/1\">",
"      Donohue JM, Pincus HA. Reducing the societal burden of depression: a review of economic costs, quality of care and effects of treatment. Pharmacoeconomics 2007; 25:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11481/abstract/2\">",
"      Sobocki P, J&ouml;nsson B, Angst J, Rehnberg C. Cost of depression in Europe. J Ment Health Policy Econ 2006; 9:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11481/abstract/3\">",
"      Cepoiu M, McCusker J, Cole MG, et al. Recognition of depression by non-psychiatric physicians--a systematic literature review and meta-analysis. J Gen Intern Med 2008; 23:25.",
"     </a>",
"    </li>",
"    <li>",
"     American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR), American Psychiatric Association, Washington, DC 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11481/abstract/5\">",
"      M&ouml;ller-Leimk&uuml;hler AM. Barriers to help-seeking by men: a review of sociocultural and clinical literature with particular reference to depression. J Affect Disord 2002; 71:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11481/abstract/6\">",
"      Dekker J, Koelen JA, Peen J, et al. Gender differences in clinical features of depressed outpatients: preliminary evidence for subtyping of depression? Women Health 2007; 46:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11481/abstract/7\">",
"      Wide J, Mok H, McKenna M, Ogrodniczuk JS. Effect of gender socialization on the presentation of depression among men: A pilot study. Can Fam Physician 2011; 57:e74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11481/abstract/8\">",
"      Rutz W. Improvement of care for people suffering from depression: the need for comprehensive education. Int Clin Psychopharmacol 1999; 14 Suppl 3:S27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11481/abstract/9\">",
"      Henkel V, Mergl R, Coyne JC, et al. Depression with atypical features in a sample of primary care outpatients: prevalence, specific characteristics and consequences. J Affect Disord 2004; 83:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11481/abstract/10\">",
"      Golden RN, Gaynes BN, Ekstrom RD, et al. The efficacy of light therapy in the treatment of mood disorders: a review and meta-analysis of the evidence. Am J Psychiatry 2005; 162:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11481/abstract/11\">",
"      Andreasen NC, Hoenk PR. The predictive value of adjustment disorders: a follow-up study. Am J Psychiatry 1982; 139:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11481/abstract/12\">",
"      Kessler RC, Chiu WT, Demler O, et al. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11481/abstract/13\">",
"      Nunes EV, Levin FR. Treatment of depression in patients with alcohol or other drug dependence: a meta-analysis. JAMA 2004; 291:1887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11481/abstract/14\">",
"      Kravitz RL, Ford DE. Introduction: chronic medical conditions and depression--the view from primary care. Am J Med 2008; 121:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11481/abstract/15\">",
"      Robinson RG. Poststroke depression: prevalence, diagnosis, treatment, and disease progression. Biol Psychiatry 2003; 54:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11481/abstract/16\">",
"      McDonald WM, Richard IH, DeLong MR. Prevalence, etiology, and treatment of depression in Parkinson's disease. Biol Psychiatry 2003; 54:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11481/abstract/17\">",
"      Jorge RE, Robinson RG, Moser D, et al. Major depression following traumatic brain injury. Arch Gen Psychiatry 2004; 61:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11481/abstract/18\">",
"      Huffman JC, Smith FA, Blais MA, et al. Recognition and treatment of depression and anxiety in patients with acute myocardial infarction. Am J Cardiol 2006; 98:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11481/abstract/19\">",
"      Whooley MA. Depression and cardiovascular disease: healing the broken-hearted. JAMA 2006; 295:2874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11481/abstract/20\">",
"      Reiche EM, Nunes SO, Morimoto HK. Stress, depression, the immune system, and cancer. Lancet Oncol 2004; 5:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11481/abstract/21\">",
"      Hanly JG, Fisk JD, McCurdy G, et al. Neuropsychiatric syndromes in patients with systemic lupus erythematosus and rheumatoid arthritis. J Rheumatol 2005; 32:1459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11481/abstract/22\">",
"      Katon W, Fan MY, Un&uuml;tzer J, et al. Depression and diabetes: a potentially lethal combination. J Gen Intern Med 2008; 23:1571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11481/abstract/23\">",
"      Kronish IM, Rieckmann N, Halm EA, et al. Persistent depression affects adherence to secondary prevention behaviors after acute coronary syndromes. J Gen Intern Med 2006; 21:1178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11481/abstract/24\">",
"      Musselman DL, Evans DL, Nemeroff CB. The relationship of depression to cardiovascular disease: epidemiology, biology, and treatment. Arch Gen Psychiatry 1998; 55:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11481/abstract/25\">",
"      Radloff, LS. The CES-D Scale. A self-report depression scale for research in the general population. Appl Psychol Measurement 1977; 1:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11481/abstract/26\">",
"      Sheikh, JI, Yesavage, JA. Geriatric Depression Scale (GDS): recent evidence and development of a shorter version. Clin Gerontol 1986; 5:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11481/abstract/27\">",
"      Williams JW Jr, Pignone M, Ramirez G, Perez Stellato C. Identifying depression in primary care: a literature synthesis of case-finding instruments. Gen Hosp Psychiatry 2002; 24:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11481/abstract/28\">",
"      Sharp LK, Lipsky MS. Screening for depression across the lifespan: a review of measures for use in primary care settings. Am Fam Physician 2002; 66:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11481/abstract/29\">",
"      Rinaldi P, Mecocci P, Benedetti C, et al. Validation of the five-item geriatric depression scale in elderly subjects in three different settings. J Am Geriatr Soc 2003; 51:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11481/abstract/30\">",
"      Rule, BG, Harvey, HZ, Dobbs, AR. Reliability of the Geriatric Depression Scale in younger adults. Clin Gerontol 1989; 9:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11481/abstract/31\">",
"      Mahoney J, Drinka TJ, Abler R, et al. Screening for depression: single question versus GDS. J Am Geriatr Soc 1994; 42:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11481/abstract/32\">",
"      Williams JW Jr, Mulrow CD, Kroenke K, et al. Case-finding for depression in primary care: a randomized trial. Am J Med 1999; 106:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11481/abstract/33\">",
"      Arroll B, Khin N, Kerse N. Screening for depression in primary care with two verbally asked questions: cross sectional study. BMJ 2003; 327:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11481/abstract/34\">",
"      Whooley MA, Avins AL, Miranda J, Browner WS. Case-finding instruments for depression. Two questions are as good as many. J Gen Intern Med 1997; 12:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11481/abstract/35\">",
"      Kroenke K, Spitzer RL, Williams JB. The Patient Health Questionnaire-2: validity of a two-item depression screener. Med Care 2003; 41:1284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11481/abstract/36\">",
"      Gilbody S, Richards D, Brealey S, Hewitt C. Screening for depression in medical settings with the Patient Health Questionnaire (PHQ): a diagnostic meta-analysis. J Gen Intern Med 2007; 22:1596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11481/abstract/37\">",
"      Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001; 16:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11481/abstract/38\">",
"      L&ouml;we B, Un&uuml;tzer J, Callahan CM, et al. Monitoring depression treatment outcomes with the patient health questionnaire-9. Med Care 2004; 42:1194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11481/abstract/39\">",
"      Beck AT, Guth D, Steer RA, Ball R. Screening for major depression disorders in medical inpatients with the Beck Depression Inventory for Primary Care. Behav Res Ther 1997; 35:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11481/abstract/40\">",
"      Beck AT, Steer RA, Ball R, Ranieri W. Comparison of Beck Depression Inventories -IA and -II in psychiatric outpatients. J Pers Assess 1996; 67:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11481/abstract/41\">",
"      BECK AT, WARD CH, MENDELSON M, et al. An inventory for measuring depression. Arch Gen Psychiatry 1961; 4:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11481/abstract/42\">",
"      Steer RA, Cavalieri TA, Leonard DM, Beck AT. Use of the Beck Depression Inventory for Primary Care to screen for major depression disorders. Gen Hosp Psychiatry 1999; 21:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11481/abstract/43\">",
"      Gilbody S, Sheldon T, Wessely S. Should we screen for depression? BMJ 2006; 332:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11481/abstract/44\">",
"      Thombs BD, Coyne JC, Cuijpers P, et al. Rethinking recommendations for screening for depression in primary care. CMAJ 2012; 184:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11481/abstract/45\">",
"      Gilbody S, House AO, Sheldon TA. Screening and case finding instruments for depression. Cochrane Database Syst Rev 2005; :CD002792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11481/abstract/46\">",
"      Gilbody S, Sheldon T, House A. Screening and case-finding instruments for depression: a meta-analysis. CMAJ 2008; 178:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11481/abstract/47\">",
"      U.S. Preventive Services Task Force. Screening for depression in adults: U.S. preventive services task force recommendation statement. Ann Intern Med 2009; 151:784.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1721 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.243-298F256B3B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_13_11481=[""].join("\n");
var outline_f11_13_11481=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H39\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Major depression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Dysthymic disorder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H260614653\">",
"      Adjustment disorder with depressed mood",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Minor depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Emotional symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Neurovegetative symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H86452216\">",
"      Gender differences",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Subtypes of major depression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Major depression with atypical features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Seasonal affective disorder",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Major depression with melancholic features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Major depression with psychotic features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Minor depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Syndromic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Etiologic",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      COMORBIDITIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Psychiatric comorbidity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Medical comorbidity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SCREENING FOR DEPRESSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Screening tools",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Five-item Geriatric Depression Scale",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Two-item screening tool",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Patient Health Questionnaire - Nine Item (PHQ-9)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Beck Depression Inventory for Primary Care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Effectiveness of depression screening",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      MAKING THE DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      History and mental status examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Psychiatric symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Medical history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Suicide risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Comorbid psychiatric disorders and family history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Comorbid medical conditions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      - Laboratory evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      WHEN TO REFER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/1721\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/1721|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?20/3/20543\" title=\"algorithm 1\">",
"      Differential dx mood disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/1721|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/13/220\" title=\"table 1\">",
"      Contributors major depression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/12/14541\" title=\"table 2\">",
"      PHQ-9 questionnaire",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/11/19639?source=related_link\">",
"      Bipolar disorder in adults: Epidemiology and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/37/39514?source=related_link\">",
"      Diagnosis and management of late-life depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/22/31080?source=related_link\">",
"      Diagnosis of psychiatric and psychologic disorders in patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/38/18025?source=related_link\">",
"      Family and couples therapy for treating depressed adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=related_link\">",
"      Initial treatment of depression in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/12/17610?source=related_link\">",
"      Medical complications of stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/58/28583?source=related_link\">",
"      Overview of psychosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/57/12179?source=related_link\">",
"      Patient information: Depression (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/6/13413?source=related_link\">",
"      Patient information: Depression in adolescents (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/41/20116?source=related_link\">",
"      Patient information: Depression in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/48/19209?source=related_link\">",
"      Pharmacotherapy for alcohol abuse and dependence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/55/16250?source=related_link\">",
"      Psychosocial and other social factors in acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41847?source=related_link\">",
"      Psychosocial treatment of alcohol abuse and dependence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/25/22936?source=related_link\">",
"      Seasonal affective disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27609?source=related_link\">",
"      Treatment of resistant depression in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/38/37481?source=related_link\">",
"      Unipolar depression in adults: Epidemiology, pathogenesis, and neurobiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/19/38201?source=related_link\">",
"      Unipolar depression in adults: Prognosis and course of illness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/15/5368?source=related_link\">",
"      Unipolar major depression with psychotic features: Epidemiology, clinical features, assessment, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/26/26025?source=related_link\">",
"      Unipolar minor depression in adults: Epidemiology, clinical presentation, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/12/35015?source=related_link\">",
"      Unipolar minor depression in adults: Management and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/40/4745?source=related_link\">",
"      Using scales to monitor symptoms and treatment of depression (measurement based care)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_13_11482="Optimizing natural fertility in couples planning pregnancy";
var content_f11_13_11482=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Optimizing natural fertility in couples planning pregnancy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/13/11482/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/13/11482/contributors\">",
"     Mark D Hornstein, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/13/11482/contributors\">",
"     William E Gibbons, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/13/11482/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/13/11482/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?11/13/11482/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?11/13/11482/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?11/13/11482/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Healthcare providers are frequently consulted by couples concerned about their fertility potential. Some couples seek this information even before attempting pregnancy or meeting criteria for subfertility. These couples are especially motivated to listen to advice concerning the impact of lifestyle factors on fertility, as well as their general health.",
"   </p>",
"   <p>",
"    Some lifestyle factors appear to affect the duration of time before achieving pregnancy; these effects tend to be small and cumulative [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11482/abstract/1\">",
"     1",
"    </a>",
"    ]. Epidemiological studies suggest that lifestyle modifications can improve fertility potential, although these interventions have not been definitively tested in randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11482/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data concerning the impact of tobacco use, body mass index, alcohol and caffeine consumption, exercise, and stress on fertility, and the implications of these findings for a couple planning pregnancy, will be reviewed here. The evaluation and treatment of subfertile couples is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/56/17287?source=see_link\">",
"     \"Overview of infertility\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3610?source=see_link\">",
"     \"Treatment of male infertility\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/18/3367?source=see_link\">",
"     \"Causes of female infertility\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/61/40921?source=see_link\">",
"     \"Evaluation of female infertility\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fertility (also called fecundity) refers to the capacity to conceive and produce offspring",
"     </li>",
"     <li>",
"      Infertility is the inability to conceive despite frequent coitus. Infertility refers to a state in which the capacity for fertility is diminished, but not necessarily absent. For this reason, the term subfertility is often used instead of infertility. Women under age 35 are evaluated for infertility after 12 months of unsuccessful attempts to conceive; women age 35 and older are evaluated after six months.",
"     </li>",
"     <li>",
"      Sterility is the inability to produce offspring.",
"     </li>",
"     <li>",
"      Fecundability is the probability of achieving a pregnancy in a single menstrual cycle.",
"     </li>",
"     <li>",
"      Subfecundity is a decrease in fecundability.",
"     </li>",
"     <li>",
"      Time to pregnancy refers to the length of time, usually measured in months, that it takes a couple to conceive. This parameter is often used in epidemiological studies as a measure of subfecundity [",
"      <a class=\"abstract\" href=\"UTD.htm?11/13/11482/abstract/4,5\">",
"       4,5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     NORMAL FERTILITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Couples should be given information about normal fertility. As the figure shows (",
"    <a class=\"graphic graphic_figure graphicRef80057 \" href=\"UTD.htm?11/24/11661\">",
"     figure 1",
"    </a>",
"    ), most pregnancies occur during the first six cycles of intercourse [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11482/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Fecundability decreases as the number of consecutive months without achieving pregnancy increases. Overall, after 12 months of unprotected intercourse, approximately 85 percent of couples will become pregnant. Over the next 36 months, approximately 50 percent of remaining couples will go on to conceive spontaneously [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11482/abstract/7\">",
"     7",
"    </a>",
"    ]. The 5 to 7 percent of couples who have not conceived after 48 months of attempted conception will only occasionally go on to achieve a spontaneous conception. Criteria for initiating an infertility evaluation vary depending on personal characteristics (eg, age) and are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/61/40921?source=see_link\">",
"     \"Evaluation of female infertility\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/44/33481?source=see_link\">",
"     \"Evaluation of male infertility\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Fertile period and frequency of coitus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Within each cycle, the fertile interval extends from approximately five days prior to ovulation to the day of ovulation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11482/abstract/8\">",
"     8",
"    </a>",
"    ]. The highest probability of conception occurs when intercourse takes place one to two days prior to ovulation and on the day of ovulation (",
"    <a class=\"graphic graphic_table graphicRef58851 \" href=\"UTD.htm?0/33/539\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11482/abstract/8-13\">",
"     8-13",
"    </a>",
"    ]. Semen quality is affected by the length of abstinence. Most data indicate that optimum semen quality, measured in terms of motility, morphology, and total sperm count, occurs when there are two to three days of ejaculatory abstinence; longer intervals are associated with lower pregnancy rates [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11482/abstract/14\">",
"     14",
"    </a>",
"    ]. The highest pregnancy rates occur in couples who have intercourse every one to two days [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11482/abstract/9,15-17\">",
"     9,15-17",
"    </a>",
"    ], but regular intercourse two to three times per week beginning soon after cessation of menses should ensure that intercourse falls within the fertile period and semen quality is optimal [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11482/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Coital position, presence or absence of female orgasm, and female",
"    <span class=\"nowrap\">",
"     position/activity",
"    </span>",
"    after male ejaculation do not appear to affect the likelihood of conception [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11482/abstract/19\">",
"     19",
"    </a>",
"    ]. Some lubricants inhibit sperm motility in vitro (eg, KY jelly, Astroglide, Touch, Replens, olive oil, saliva) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11482/abstract/20-24\">",
"     20-24",
"    </a>",
"    ]. A secondary analysis of couples in a prospective time-to-pregnancy study found no difference in fecundability between those who used and didn&rsquo;t use lubricants (primarily Astroglide, KY Jelly, or Pre-seed) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11482/abstract/25\">",
"     25",
"    </a>",
"    ]. Although there are no compelling data to suggest that lubricant use impairs fertility, the use of lubricants, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/0/13316?source=see_link\">",
"     mineral oil",
"    </a>",
"    , canola oil, or hydroxyethylcellulose-base (Pre-Seed), may be prudent.",
"   </p>",
"   <p>",
"    Women can attempt to predict the time of ovulation by tracking changes in cervical mucus (highest probability of conception is on day of peak production of slippery clear mucus) or by using a kit to measure urinary luteinizing hormone (home ovulation test). This may be useful to decrease the time to conception [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11482/abstract/26\">",
"     26",
"    </a>",
"    ], particularly in women with irregular cycles or couples who have intercourse infrequently [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11482/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/6/26724?source=see_link&amp;anchor=H8#H8\">",
"     \"Evaluation of the menstrual cycle and timing of ovulation\", section on 'Measurement of LH surge'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Effect of age",
"    </span>",
"    &nbsp;&mdash;&nbsp;The probability of conception is also highly dependent upon maternal, and to a lesser extent paternal, age. In a large well-designed study, the probability of clinical pregnancy following intercourse on the most fertile day of the cycle in women of assumed fertility aged 19 to 26 years, 27 to 34 years, and 35 to 39 years was about 50, 40, and 30 percent, respectively, if the male partner was the same age, but 45, 40, and 15 percent, respectively, if he was five years older [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11482/abstract/27\">",
"     27",
"    </a>",
"    ]. Couples should be informed that delayed childbearing can decrease the probability of successful conception, and they should take this into account in family and career planning. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/7/31865?source=see_link\">",
"     \"Effect of advanced age on fertility and pregnancy in women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/54/30567?source=see_link\">",
"     \"Effect of advanced paternal age on fertility and pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     LIMITATIONS OF DATA",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no large-scale, randomized, clinical trials examining the effect of lifestyle issues such as cigarette smoking, body mass index, stress, or alcohol or caffeine consumption on fertility. Most studies are observational and subject to many potential biases. As an example, numerous investigators have reported that primary tubal infertility is increased in women who report a history of many sexual partners, an earlier age at first intercourse, and cigarette smoking. However, women with more sexual partners and an earlier age at first intercourse may also be more likely to smoke cigarettes; thus, it is often difficult to definitively determine if cigarette smoking is an independent contributor to infertility or whether cigarette smoking is largely associated with infertility through other exposures, such as sexually transmitted infections [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11482/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. In addition, women who smoke cigarettes tend to consume more alcohol and caffeine than women who do not smoke. This raises the possibility that the relationship of cigarette smoking and reduced fertility may influence observations of an association between alcohol and caffeine consumption and diminished fertility.",
"   </p>",
"   <p>",
"    In many of the studies discussed below, attempts were made to control for some of the potential confounding interactions through the use of logistic regression and multivariate analyses. However, the absence of data from randomized controlled trials is a major weakness of the evidence in this area.",
"   </p>",
"   <p>",
"    An additional limitation is that there is no biomarker that can be measured to indicate the potential for human conception [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11482/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     TOBACCO USE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of tobacco by the female partner, and possibly by the male partner, is associated with subfertility [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11482/abstract/31\">",
"     31",
"    </a>",
"    ]. As much as 13 percent of infertility may be attributed to cigarette smoking [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11482/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H647595133\">",
"    <span class=\"h2\">",
"     Female partner",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 23 percent of American women age 18 or over smoke cigarettes [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11482/abstract/33\">",
"     33",
"    </a>",
"    ], and up to 13 percent of subfertility has been attributable to cigarette smoking [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11482/abstract/34\">",
"     34",
"    </a>",
"    ]. Studies of the impact of smoking on fertility have typically analyzed the effects of \"cigarettes smoked per day\" on fecundability. Most series report that fecundability is decreased if the female partner smokes greater than 10 cigarettes per day. Possible mechanisms include tubal changes, cervical changes, damage to gametes, and increase in spontaneous abortion and ectopic pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11482/abstract/29,34,35\">",
"     29,34,35",
"    </a>",
"    ]. In addition, numerous studies linking smoking to early menopause suggest that cigarette smoking causes premature depletion of the ovarian pool of oocytes and premature aging of the ovary by one to four years [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11482/abstract/34,36\">",
"     34,36",
"    </a>",
"    ]. Components of cigarette smoke may cause oxidative stress and DNA damage in the ovarian follicle [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11482/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. Ovarian aging is thought to be a major contributor to unexplained infertility.",
"   </p>",
"   <p>",
"    These relationships were best illustrated in a meta-analysis including data from almost 11,000 smoking women and 20,000 nonsmokers [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11482/abstract/39\">",
"     39",
"    </a>",
"    ]. Cigarette smoking by the female partner was associated with a statistically significant increase in infertility compared to nonsmokers, OR 1.60 (95% CI 1.34-1.91). Although only observational studies were included, the evidence was compelling because of the consistency of the effect across different study designs, sample sizes, and types of outcome. Others have shown that the time to achieve pregnancy also increases with the number of cigarettes smoked per day (",
"    <a class=\"graphic graphic_figure graphicRef74093 \" href=\"UTD.htm?42/45/43741\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11482/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An additional concern is that subfertility in smokers cannot necessarily be overcome by assisted reproductive technology. As an example, a meta-analysis showed that the odds of pregnancy per number of in vitro fertilization cycles was significantly lower in smokers compared to nonsmokers: OR 0.66 (95% CI 0.49-0.88) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11482/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Components of cigarette smoke are known to damage ovarian follicles and cause premature aging of the ovary. It is unclear whether smoking by a pregnant woman also damages the ovaries of her fetus [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11482/abstract/41\">",
"     41",
"    </a>",
"    ]. This damage might be demonstrated by showing an increase in infertility in women whose mothers smoked during their pregnancy. One study of 221 couples examined the effect of in-utero exposure to cigarette smoke on the fertility of the female partner and found fecundability was reduced (fecundability ratio 0.5, 95% CI 0.4-0.8) among women exposed to cigarette smoke in-utero [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11482/abstract/42\">",
"     42",
"    </a>",
"    ]. This association was present after adjusting for age of the female partner, frequency of intercourse, current smoking status, age at menarche, childhood exposure to cigarette smoke, body mass of the female partner, alcohol and caffeine consumption, educational level, and reproductive history.",
"   </p>",
"   <p>",
"    There may also be adverse reproductive effects of maternal smoking on male fetuses. An epidemiologic study reported that adult male offspring of mothers who smoked greater than 10",
"    <span class=\"nowrap\">",
"     cigarettes/day",
"    </span>",
"    during pregnancy had lower sperm counts than the sons of nonsmokers [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11482/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H647595140\">",
"    <span class=\"h2\">",
"     Male partner",
"    </span>",
"    &nbsp;&mdash;&nbsp;An analysis of 27 studies addressing the effect of smoking on sperm concentration, motility, and morphology in fertile and infertile men found a modest reduction in semen quality and altered hormone levels among smokers compared to nonsmokers, but did not find a reduction in male fertility associated with paternal smoking [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11482/abstract/44\">",
"     44",
"    </a>",
"    ]. Studies of noninfertile male smokers and nonsmokers reported an average 23 percent decrease in sperm concentration and 13 percent decrease in sperm motility among the smokers [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11482/abstract/44\">",
"     44",
"    </a>",
"    ]. The effects of smoking are dose dependent.",
"   </p>",
"   <p>",
"    A possible effect on male fertility or a secondary effect on female fertility cannot be definitively excluded. Studies evaluating the effect of smoking by the male partner on the success rate of in vitro fertilization and intracytoplasmic sperm injection reported a significant decrease in the number of pregnancies achieved in the subfertile population [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11482/abstract/45,46\">",
"     45,46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Cessation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Observational studies suggest that much of the subfertility associated with smoking can be reversed within a year of cessation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11482/abstract/31,47-49\">",
"     31,47-49",
"    </a>",
"    ]. Given the multiple health risks associated with cigarette smoking, cessation should be encouraged irrespective of fertility and pregnancy issues. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/62/22505?source=see_link\">",
"     \"Secondhand smoke exposure: Effects in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The American Thoracic Society (ATS) statement on cigarette smoking and health, as well as other ATS guidelines, can be accessed through the ATS web site at",
"    <a class=\"external\" href=\"file://www.thoracic.org/site-map.php\">",
"     www.thoracic.org/site-map.php",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    The physician should emphasize the need for couples to give each other social support in their attempts to quit smoking. Success in quitting may not be as high if either partner continues smoking and continued smoking by one partner puts the other partner at risk of sequelae from second hand smoke. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/3/23609?source=see_link\">",
"     \"Overview of smoking cessation management in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     BODY MASS INDEX",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overweight and underweight women are at risk of subfertility, as well as other adverse effects on health. The effect of weight on male fertility is less clear. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/35/30266?source=see_link\">",
"     \"Health hazards associated with obesity in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H647595147\">",
"    <span class=\"h2\">",
"     Female partner",
"    </span>",
"    &nbsp;&mdash;&nbsp;In practice, the distinction between overweight and obesity is based upon the body mass index (BMI), which is the most practical way to evaluate the degree of excess weight. It is calculated from the weight and square of the height as follows: BMI = body weight (kg) divided by stature (meters) squared. The BMI can also be obtained from a nomogram (",
"    <a class=\"graphic graphic_figure graphicRef65305 \" href=\"UTD.htm?12/3/12351\">",
"     figure 3",
"    </a>",
"    ), table (",
"    <a class=\"graphic graphic_table graphicRef63600 graphicRef74762 \" href=\"UTD.htm?28/43/29361\">",
"     table 2A-B",
"    </a>",
"    ) or calculator (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?39/41/40593?source=see_link\">",
"     calculator 1",
"    </a>",
"    ). The definition of overweight and obesity varies by race. Overweight for whites is defined as a BMI between 25 and 29.9",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    and obesity is defined as a BMI of 30",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    or more. These definitions are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/20/12615?source=see_link\">",
"     \"Screening for and clinical evaluation of obesity in adults\"",
"    </a>",
"    .) The National",
"    <sup>",
"    </sup>",
"    Health and Nutrition Examination Survey (NHANES), a nationally",
"    <sup>",
"    </sup>",
"    representative sample of the US population.",
"    <sup>",
"    </sup>",
"    reported that over 60 percent of American women were overweight (BMI &ge;25) and 33 percent were obese (BMI &ge;25) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11482/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most studies report a BMI greater than 27",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    or a BMI less than 17",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    is associated with increased anovulatory infertility [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11482/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. The association between high BMI and subfertility appears to be related to insulin resistance leading to insulin excess [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11482/abstract/53\">",
"     53",
"    </a>",
"    ]. Hyperinsulinemia may lead to androgen excess by reducing sex hormone-binding globulin synthesis and by stimulating ovarian androgen production rates. Excess androgen, in turn, is a major factor leading to altered ovarian physiology and anovulation. Obesity-associated hyperleptinemia may be an additional factor involved in anovulation, not only through the induction of insulin resistance, but also through direct impairment of ovarian function. Factors other than anovulation also likely play a role in obesity-related subfertility [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11482/abstract/54\">",
"     54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/36/39495?source=see_link\">",
"     \"Diagnosis of polycystic ovary syndrome in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/11/29882?source=see_link&amp;anchor=H7#H7\">",
"     \"The impact of obesity on fertility and pregnancy\", section on 'Subfertility'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The association between low BMI and infertility is also related to anovulation, especially in women who exercise excessively",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    have low caloric intake. These women may have hypothalamic amenorrhea (suppression of pulsatile GnRH secretion from the hypothalamus resulting in decreased secretion of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) and therefore loss of ovarian cyclicity and estrogen deficiency). Changes in leptin may also be involved. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/3/36919?source=see_link\">",
"     \"Amenorrhea and infertility associated with exercise\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/2/23593?source=see_link\">",
"     \"Eating disorders: Epidemiology, pathogenesis, clinical features, and course of illness\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H647595154\">",
"    <span class=\"h2\">",
"     Male partner",
"    </span>",
"    &nbsp;&mdash;&nbsp;The impact of the male partner's BMI on fertility has not been examined extensively. Some observational and animal data suggest an association between increasing male BMI and lower pregnancy rates [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11482/abstract/55-57\">",
"     55-57",
"    </a>",
"    ]. There is consistent evidence that obesity affects reproductive hormone levels, but studies have reported conflicting results on the effect of obesity on semen parameters [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11482/abstract/58-61\">",
"     58-61",
"    </a>",
"    ]. Weight reduction can correct the hormonal imbalance; the effect of weight loss on semen parameters and pregnancy rate has not been studied.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Optimum weight",
"    </span>",
"    &nbsp;&mdash;&nbsp;A BMI of 18.5 to 25",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    is associated with little or no increased health risks and, for this reason, is desirable for both women and men irrespective of fertility issues.",
"   </p>",
"   <p>",
"    Weight reduction in obese, infertile women appears to be associated with an increase in the frequency of ovulation and the likelihood of pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11482/abstract/62-67\">",
"     62-67",
"    </a>",
"    ]. There are no randomized trials evaluating the effect of weight reduction alone specifically in this population, but a randomized trial involving overweight and obese",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    citrate-resistant PCOS patients showed that weight reduction enhanced ovulation in this subgroup of obese infertile women [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11482/abstract/68\">",
"     68",
"    </a>",
"    ]. In this trial, 96 overweight and obese clomiphene citrate-resistant women with PCOS were randomly assigned to six weeks of treatment with one of three interventions: (1) structured exercise training plus hypocaloric diet (group A), (2) observation for two weeks then one cycle of clomiphene citrate (group B), or (3) structured exercise training plus hypocaloric diet and one cycle of clomiphene citrate after two weeks (group C). After six weeks, groups A and C had significant reductions in body weight and BMI, while group B remained stable. Ovulation rates in the three groups were approximately 12, 9, and 37 percent, respectively. These data suggest that, in overweight and obese women with PCOS who are resistant to clomiphene citrate, diet and exercise is an effective strategy to increase the probability of ovulation, particularly with clomiphene citrate. Whether these interventions will be effective in other groups of obese infertile women needs to be determined.",
"   </p>",
"   <p>",
"    Weight reduction is best achieved by a combination of reducing calorie intake (dieting) and increasing calorie expenditure (exercise). However, for the female partner, exercise at levels more than 60 minutes per day has been associated with an increase in primary ovulatory infertility [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11482/abstract/69\">",
"     69",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/45/13016?source=see_link\">",
"     \"Overview of therapy for obesity in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/3/36919?source=see_link\">",
"     \"Amenorrhea and infertility associated with exercise\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Underweight infertile women may benefit from weight gain, which may improve both the frequency of ovulation and the likelihood of pregnancy. Studies showing these benefits generally lack a control group and are not prospective, randomized trials. As an example, a study of 26 infertile women with a mean BMI of 19.2",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    employed counseling by a dietitian and physician directed advice to increase BMI [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11482/abstract/70\">",
"     70",
"    </a>",
"    ]. These women gained a mean 3.7 kg and 73 percent conceived after these interventions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     EXERCISE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4029032\">",
"    <span class=\"h2\">",
"     Female partner",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combination of intensity and duration of exercise can affect female fertility, but the specific type of exercise does not appear to be a factor. In some epidemiological studies,",
"    <span class=\"nowrap\">",
"     vigorous/intense",
"    </span>",
"    physical activity has been associated with ovulatory infertility [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11482/abstract/69,71\">",
"     69,71",
"    </a>",
"    ], while others have not observed a significant association [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11482/abstract/72\">",
"     72",
"    </a>",
"    ]. Baseline patient characteristics appear to play a role. In a well-designed study of Danish women, vigorous physical activity (running, fast cycling, aerobics, swimming, gymnastics) was associated with a reduction in fecundity; however, the effect was confined to women with a BMI &lt;25",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"     ;",
"    </span>",
"    there was a slightly positive effect of all levels of exercise among overweight and obese women [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11482/abstract/73\">",
"     73",
"    </a>",
"    ]. In women undergoing in vitro fertilization, another study noted that &ge;4 hours of strenuous exercise weekly over a period of years was associated with poorer outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11482/abstract/74\">",
"     74",
"    </a>",
"    ]. Based on these data, we suggest women with a BMI &lt;25",
"    <span class=\"nowrap\">",
"     kg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    who are attempting to conceive limit vigorous exercise to less than five hours per week.",
"   </p>",
"   <p>",
"    The effects of strenuous exercise on fertility could be related to (1) reduced progesterone production during the luteal phase of the menstrual cycle in ovulatory women (ie, luteal phase defect), (2) alterations in GnRH production, LH and FSH secretion, and estradiol production and metabolism, resulting in anovulation, or (3) changes in leptin levels [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11482/abstract/75-77\">",
"     75-77",
"    </a>",
"    ]. Other factors may include decreased body fat and changes in diet, such as an increase in fiber and a decrease in fat intake, in women who exercise strenuously. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/3/36919?source=see_link\">",
"     \"Amenorrhea and infertility associated with exercise\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    From a population perspective, inadequate levels of exercise associated with obesity may be a more common cause of anovulation and subsequent infertility than exercise associated anovulation (see",
"    <a class=\"local\" href=\"#H9\">",
"     'Body mass index'",
"    </a>",
"    above) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11482/abstract/78,79\">",
"     78,79",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/46/28394?source=see_link&amp;anchor=H32#H32\">",
"     \"Overview of the benefits and risks of exercise\", section on 'Exercise prescription'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20448227\">",
"    <span class=\"h2\">",
"     Male partner",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relationship between fertility and exercise in the male has not been well characterized; however, one large retrospective study examined the association between regular physical exercise and semen quality in 2261 men whose partners were undergoing in vitro fertilization (IVF) [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11482/abstract/80\">",
"     80",
"    </a>",
"    ]. Overall, none of the semen parameters studied was affected by exercise; however, men who bicycled &ge;5",
"    <span class=\"nowrap\">",
"     hours/week",
"    </span>",
"    demonstrated lower sperm concentrations and lower numbers of total motile sperm than their non-exercising counterparts. Results were not influenced by age, BMI or a history of male infertility.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     ALCOHOL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 70 percent of American women consume alcoholic beverages; 25 percent report consuming more than four drinks per week. Investigators have used the concept of a \"standardized alcoholic drink\" in most studies of ethanol and infertility. A standardized drink is typically defined as 12 ounces of beer, 5 ounces of wine, or 1.5 ounces of spirits, which is the equivalent of 12 grams of ethanol.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H647595161\">",
"    <span class=\"h2\">",
"     Female partner",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most observational studies have reported moderate and heavy female drinkers tend to take longer to achieve a pregnancy and are at higher risk of undergoing an infertility evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11482/abstract/81-85\">",
"     81-85",
"    </a>",
"    ]. Others have not noted an adverse effect of moderate alcohol intake on fertility [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11482/abstract/86,87\">",
"     86,87",
"    </a>",
"    ], nor a difference in risk of ovulatory dysfunction between women with high versus low alcohol intake [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11482/abstract/88\">",
"     88",
"    </a>",
"    ]. Heavy alcohol intake is typically defined as more than 14 drinks per week and moderate intake is usually defined as 3 to 13 drinks per week, but these definitions are arbitrary and vary in different studies. The characteristics of the dose-response relationship require additional study.",
"   </p>",
"   <p>",
"    Whether alcohol use impairs success of in vitro fertilization is unclear due to lack of studies [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11482/abstract/89\">",
"     89",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H647595168\">",
"    <span class=\"h2\">",
"     Male partner",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heavy alcohol use by the male partner is related to abnormalities in gonadal function, including reduced testosterone production, impotence, and decreased spermatogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11482/abstract/90-92\">",
"     90-92",
"    </a>",
"    ]. However, moderate alcohol intake by the male partner does not appear to be associated with decreased fertility.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Optimum intake",
"    </span>",
"    &nbsp;&mdash;&nbsp;Moderate alcohol intake by the male partner does not appear to be associated with decreased fertility. Alcohol consumption by the female partner appears to decrease fertility and can affect the developing fetus, but the characteristics of the dose-response relationship require additional study. For females, the US Surgeon General and the Secretary of Health and Human Services recommend abstinence at conception and during pregnancy because a safe level of prenatal alcohol consumption has not been determined. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/61/38874?source=see_link\">",
"     \"Overview of the risks and benefits of alcohol consumption\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     DIET",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relationship between diet and fertility is not well-defined, except at dietary extremes (see",
"    <a class=\"local\" href=\"#H9\">",
"     'Body mass index'",
"    </a>",
"    above). All of the data in humans are from observational studies.",
"   </p>",
"   <p>",
"    One of the largest of these studies was a prospective cohort study of over 18,000 married, premenopausal women without a history of infertility who attempted pregnancy or became pregnant [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11482/abstract/72,93-97\">",
"     72,93-97",
"    </a>",
"    ]. Based on their own data and that from other studies, the authors considered the following dietary habits components of a \"fertility diet:\" higher monounsaturated to trans fat ratio, high percentage of protein from vegetable rather than animal sources, low glycemic index carbohydrates, high fat dairy foods, and use of iron and multivitamin supplements. Healthy women whose diet reflected this composition had a significantly reduced risk of ovulatory disorder infertility. They hypothesized that this diet was favorable to glucose homeostasis and insulin sensitivity, factors that play a role in ovulatory function. The results were based on dietary recall, thus were subject to recall bias. Other smaller observational studies have supported the beneficial effects of a Mediterranean diet on achieving natural or assisted conception [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11482/abstract/98,99\">",
"     98,99",
"    </a>",
"    ]. There is no harm to such diets, but insufficient data at this time to recommend dietary changes solely for enhancement of fertility.",
"   </p>",
"   <p>",
"    Dietary habits may also affect male fertility. In one study comparing normospermic to oligoasthenoteratospermic men, normospermic men had higher consumption of skimmed milk, shellfish, tomatoes, and lettuce and significantly lower consumption of dairy and meat processed products, suggesting that frequent intake of the latter food groups negatively affects semen quality [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11482/abstract/100\">",
"     100",
"    </a>",
"    ]. Furthermore, when men with defects in sperm parameters associated with varicocele made",
"    <span class=\"nowrap\">",
"     lifestyle/dietary",
"    </span>",
"    changes (eg, reduced intake of caffeine, alcohol, and tobacco and increased intake of fruits and vegetables), semen quality improved to within normal WHO parameters in 40 of the 52 patients (76 percent) and the remaining 12 men all had improvement, although not statistically significant [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11482/abstract/101\">",
"     101",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In both women and men,",
"    <span class=\"nowrap\">",
"     undiagnosed/untreated",
"    </span>",
"    celiac disease may cause subfertility, which resolves by adopting a gluten-free diet. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40650?source=see_link\">",
"     \"Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     CAFFEINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 20 percent of adult Americans consume greater than 300 mg of caffeine daily (",
"    <a class=\"graphic graphic_table graphicRef79304 \" href=\"UTD.htm?30/43/31422\">",
"     table 3",
"    </a>",
"    ). Some studies have reported that increased caffeine consumption (eg, &gt;300 to 500 mg) is associated with a modest, but statistically significant decrease in fecundability, while others have not found an adverse effect. The widespread consumption of caffeine at doses associated with subfertility makes it a potentially important contributor to fertility problems. These issues are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/35/20026?source=see_link\">",
"     \"The effects of caffeine on reproductive outcomes in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H647595203\">",
"    <span class=\"h2\">",
"     Female partner",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanism by which caffeine consumption may be linked to infertility is unclear. Caffeine consumption may increase estrogen production",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    decrease estrogen metabolism [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11482/abstract/102\">",
"     102",
"    </a>",
"    ]. Caffeine consumption has also been linked to tubal factor infertility and endometriosis associated infertility [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11482/abstract/103\">",
"     103",
"    </a>",
"    ]. Most studies were done in coffee drinkers and do not account for other sources of caffeine or other substances in coffee that may affect fertility.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H647595210\">",
"    <span class=\"h2\">",
"     Male partner",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no strong evidence that caffeine consumption by the male partner influences fertility. Whether caffeine consumption impairs success of in vitro fertilization is unclear due to lack of studies [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11482/abstract/89\">",
"     89",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Suggested intake",
"    </span>",
"    &nbsp;&mdash;&nbsp;Female fertility does not appear affected by caffeine intake less than 200 mg per day; therefore, women contemplating pregnancy can probably have one or two 6 to 8 ounce cups of coffee per day (",
"    <a class=\"graphic graphic_table graphicRef79304 \" href=\"UTD.htm?30/43/31422\">",
"     table 3",
"    </a>",
"    ) without impairing their ability to conceive. There is no evidence to support limiting caffeine intake in the male partner.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     STRESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many observational studies suggest that stress can cause infertility; and in turn, the diagnosis and treatment of infertility can cause stress. No clinical trial has demonstrated definitively that reducing stress prior to infertility treatment improves pregnancy rates. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/52/22343?source=see_link\">",
"     \"Psychological stress and infertility\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a meta-analysis that pooled 31 prospective trials examining the association between stress, distress and assisted reproductive technology (ART) outcomes, small but statistically significant negative correlations were observed between ART outcomes and stress and anxiety [",
"    <a class=\"abstract\" href=\"UTD.htm?11/13/11482/abstract/104\">",
"     104",
"    </a>",
"    ]. Importantly, however, the association with anxiety disappeared when livebirth rates were examined, and too few trials using stress were included to allow statistical analysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     ENVIRONMENTAL TOXINS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potential environmental toxins and their effects on the menstrual cycle, fertility, and pregnancy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/40/4746?source=see_link\">",
"     \"Occupational and environmental risks to reproduction in females\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     RECREATIONAL OR ILLICIT DRUGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no good data on the effects of recreational or illicit drug use on fertility. These drugs should be avoided because of their general health risks and adverse effects during pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/12/6346?source=see_link\">",
"     \"Overview of illicit drug use in pregnant women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     LIFESTYLE EFFECTS ON ESTABLISHED PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cigarette smoking, high BMI, and alcohol and caffeine consumption can have a significant adverse impact on pregnancy and fetal outcomes. The combined impact of these exposures on both fertility and pregnancy outcome emphasizes the importance of lifestyle interventions for the couple planning a pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/25/16794?source=see_link\">",
"     \"Preconception evaluation and counseling\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cigarette smoking during pregnancy may increase the risk of spontaneous abortion, intrauterine growth restriction, or preterm delivery. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/53/27482?source=see_link\">",
"       \"Smoking and pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A body mass index greater than 30",
"      <span class=\"nowrap\">",
"       kg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      in the pregnant woman is associated with an increased risk of congenital malformations, preeclampsia, gestational diabetes, fetal macrosomia, and cesarean delivery. Underweight women are at increased risk of low birth weight newborns. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/11/29882?source=see_link\">",
"       \"The impact of obesity on fertility and pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Alcohol consumption during pregnancy can cause fetal alcohol syndrome. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/38/41575?source=see_link\">",
"       \"Alcohol intake and pregnancy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/4/28746?source=see_link\">",
"       \"Infants of mothers with substance abuse\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      High caffeine intake appears to increase the risk of spontaneous abortion. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/23/19834?source=see_link\">",
"       \"Spontaneous abortion: Risk factors, etiology, clinical manifestations, and diagnostic evaluation\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     FUTURE DIRECTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;One paradigm to increase fertility is to develop population-based efforts to prevent infertility. Public health interventions to prevent infertility would begin early in adolescence and include efforts to:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reduce the prevalence of sexually transmitted diseases, the most important cause of tubal factor infertility (minimize the number of sexual partners, use barrier contraceptives, screen regularly for sexually transmitted diseases, etc) [",
"      <a class=\"abstract\" href=\"UTD.htm?11/13/11482/abstract/28\">",
"       28",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/12/35018?source=see_link\">",
"       \"Prevention of sexually transmitted infections\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Advise women about the relationship between chronological age and fertility potential. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/7/31865?source=see_link\">",
"       \"Effect of advanced age on fertility and pregnancy in women\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Maintain appropriate BMI throughout life. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/35/30266?source=see_link\">",
"       \"Health hazards associated with obesity in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Reduce exposure to cocaine, marijuana, tobacco products, alcohol, and possibly caffeine [",
"      <a class=\"abstract\" href=\"UTD.htm?11/13/11482/abstract/105\">",
"       105",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/53/27482?source=see_link\">",
"       \"Smoking and pregnancy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/12/6346?source=see_link\">",
"       \"Overview of illicit drug use in pregnant women\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/38/41575?source=see_link\">",
"       \"Alcohol intake and pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lifestyle factors can affect the duration of time before achieving pregnancy and modifying these factors may enhance fertility. The recommendations below are based upon data from observational studies; no randomized trials have been performed.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Couples should be informed that delayed childbearing, especially after age 30, can decrease the probability of successful conception, and they should take this into account in family and career planning. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Effect of age'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest sexual intercourse two to three times per week to ensure that intercourse falls within the fertile period (up to two days before ovulation) and semen quality is optimal (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Fertile period and frequency of coitus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend smoking cessation for couples who smoke based on the overall health benefits of smoking cessation (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Use of tobacco by the female partner, and possibly the male partner, appears to be associated with subfertility. For couples planning pregnancy, observational studies suggest fertility is enhanced when use of tobacco products is terminated. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Tobacco use'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A body mass index greater than 27",
"      <span class=\"nowrap\">",
"       kg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      or less than 17",
"      <span class=\"nowrap\">",
"       kg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      is associated with an increased risk of anovulatory infertility. The former is often related to polycystic ovary syndrome and the latter is often related to amenorrhea caused by excessive exercise or poor caloric intake (eg, eating disorders). We suggest couples try to achieve a body mass index of 18.5 to 25",
"      <span class=\"nowrap\">",
"       kg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Women in this weight range are less likely to have ovulatory dysfunction than women at either extreme of body mass index. This range is associated with little or no increased health risks and, for this reason, is desirable for both women and men. There is little information on the relationship between male fertility and body mass index. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Body mass index'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Moderate and heavy female drinkers tend to take longer to achieve a pregnancy and are at higher risk of undergoing an infertility evaluation. We suggest that women who are attempting to conceive avoid all alcohol, given a safe level of prenatal alcohol consumption with respect to the fetus has not been determined (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Moderate alcohol intake by the male partner does not appear to be associated with decreased fertility. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Alcohol'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      It is unclear whether high caffeine consumption affects female fertility; it does not appear to affect male fertility. We suggest women contemplating pregnancy limit caffeine intake to no more than one or two cups of coffee per day (total of 200 mg caffeine) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Caffeine'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/1\">",
"      Hassan MA, Killick SR. Negative lifestyle is associated with a significant reduction in fecundity. Fertil Steril 2004; 81:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/2\">",
"      Anderson K, Norman RJ, Middleton P. Preconception lifestyle advice for people with subfertility. Cochrane Database Syst Rev 2010; :CD008189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/3\">",
"      Huang H, Hansen KR, Factor-Litvak P, et al. Predictors of pregnancy and live birth after insemination in couples with unexplained or male-factor infertility. Fertil Steril 2012; 97:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/4\">",
"      Joffe M, Key J, Best N, et al. Studying time to pregnancy by use of a retrospective design. Am J Epidemiol 2005; 162:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/5\">",
"      Gnoth C, Godehardt D, Godehardt E, et al. Time to pregnancy: results of the German prospective study and impact on the management of infertility. Hum Reprod 2003; 18:1959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/6\">",
"      Zinaman MJ, Clegg ED, Brown CC, et al. Estimates of human fertility and pregnancy loss. Fertil Steril 1996; 65:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/7\">",
"      Gnoth C, Godehardt E, Frank-Herrmann P, et al. Definition and prevalence of subfertility and infertility. Hum Reprod 2005; 20:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/8\">",
"      Dunson DB, Baird DD, Wilcox AJ, Weinberg CR. Day-specific probabilities of clinical pregnancy based on two studies with imperfect measures of ovulation. Hum Reprod 1999; 14:1835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/9\">",
"      Wilcox AJ, Weinberg CR, Baird DD. Timing of sexual intercourse in relation to ovulation. Effects on the probability of conception, survival of the pregnancy, and sex of the baby. N Engl J Med 1995; 333:1517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/10\">",
"      Trussell J, Rodr&iacute;guez G, Ellertson C. New estimates of the effectiveness of the Yuzpe regimen of emergency contraception. Contraception 1998; 57:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/11\">",
"      Weinberg CR, Gladen BC, Wilcox AJ. Models relating the timing of intercourse to the probability of conception and the sex of the baby. Biometrics 1994; 50:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/12\">",
"      Masarotto G, Romualdi C. Probability of conception on different days of the menstrual cycle: an ongoing exercise. Adv Contracept 1997; 13:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/13\">",
"      Bilian X, Heng Z, Shang-chun W, et al. Conception probabilities at different days of menstrual cycle in Chinese women. Fertil Steril 2010; 94:1208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/14\">",
"      Jurema MW, Vieira AD, Bankowski B, et al. Effect of ejaculatory abstinence period on the pregnancy rate after intrauterine insemination. Fertil Steril 2005; 84:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/15\">",
"      Elzanaty S, Malm J, Giwercman A. Duration of sexual abstinence: epididymal and accessory sex gland secretions and their relationship to sperm motility. Hum Reprod 2005; 20:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/16\">",
"      Levitas E, Lunenfeld E, Weiss N, et al. Relationship between the duration of sexual abstinence and semen quality: analysis of 9,489 semen samples. Fertil Steril 2005; 83:1680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/17\">",
"      Check JH, Epstein R, Long R. Effect of time interval between ejaculations on semen parameters. Arch Androl 1991; 27:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/18\">",
"      Stanford JB, Dunson DB. Effects of sexual intercourse patterns in time to pregnancy studies. Am J Epidemiol 2007; 165:1088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/19\">",
"      Practice Committee of American Society for Reproductive Medicine in collaboration with Society for Reproductive Endocrinology and Infertility. Optimizing natural fertility. Fertil Steril 2008; 90:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/20\">",
"      Agarwal A, Deepinder F, Cocuzza M, et al. Effect of vaginal lubricants on sperm motility and chromatin integrity: a prospective comparative study. Fertil Steril 2008; 89:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/21\">",
"      Frishman GN, Luciano AA, Maier DB. Evaluation of Astroglide, a new vaginal lubricant: effects of length of exposure and concentration on sperm motility. Fertil Steril 1992; 58:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/22\">",
"      Anderson L, Lewis SE, McClure N. The effects of coital lubricants on sperm motility in vitro. Hum Reprod 1998; 13:3351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/23\">",
"      Goldenberg RL, White R. The effect of vaginal lubricants on sperm motility in vitro. Fertil Steril 1975; 26:872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/24\">",
"      Kutteh WH, Chao CH, Ritter JO, Byrd W. Vaginal lubricants for the infertile couple: effect on sperm activity. Int J Fertil Menopausal Stud 1996; 41:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/25\">",
"      Steiner AZ, Long DL, Tanner C, Herring AH. Effect of vaginal lubricants on natural fertility. Obstet Gynecol 2012; 120:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/26\">",
"      Tiplady S, Jones G, Campbell M, et al. Home ovulation tests and stress in women trying to conceive: a randomized controlled trial. Hum Reprod 2013; 28:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/27\">",
"      Dunson DB, Colombo B, Baird DD. Changes with age in the level and duration of fertility in the menstrual cycle. Hum Reprod 2002; 17:1399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/28\">",
"      Cramer DW, Goldman MB, Schiff I, et al. The relationship of tubal infertility to barrier method and oral contraceptive use. JAMA 1987; 257:2446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/29\">",
"      Phipps WR, Cramer DW, Schiff I, et al. The association between smoking and female infertility as influenced by cause of the infertility. Fertil Steril 1987; 48:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/30\">",
"      Louis GM, Cooney MA, Lynch CD, Handal A. Periconception window: advising the pregnancy-planning couple. Fertil Steril 2008; 89:e119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/31\">",
"      Howe G, Westhoff C, Vessey M, Yeates D. Effects of age, cigarette smoking, and other factors on fertility: findings in a large prospective study. Br Med J (Clin Res Ed) 1985; 290:1697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/32\">",
"      Practice Committee of the American Society for Reproductive Medicine. Smoking and infertility: a committee opinion. Fertil Steril 2012; 98:1400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/33\">",
"      D'Angelo D, Williams L, Morrow B, et al. Preconception and interconception health status of women who recently gave birth to a live-born infant--Pregnancy Risk Assessment Monitoring System (PRAMS), United States, 26 reporting areas, 2004. MMWR Surveill Summ 2007; 56:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/34\">",
"      Practice Committee of the American Society for Reproductive Medicine. Smoking and infertility. Fertil Steril 2004; 81:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/35\">",
"      Bouyer J, Coste J, Fernandez H, Job-Spira N. [Tobacco and ectopic pregnancy. Arguments in favor of a causal relation]. Rev Epidemiol Sante Publique 1998; 46:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/36\">",
"      Cramer DW, Barbieri RL, Xu H, Reichardt JK. Determinants of basal follicle-stimulating hormone levels in premenopausal women. J Clin Endocrinol Metab 1994; 79:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/37\">",
"      Paszkowski T, Clarke RN, Hornstein MD. Smoking induces oxidative stress inside the Graafian follicle. Hum Reprod 2002; 17:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/38\">",
"      Sink&oacute; I, M&oacute;rocz M, Z&aacute;dori J, et al. Effect of cigarette smoking on DNA damage of human cumulus cells analyzed by comet assay. Reprod Toxicol 2005; 20:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/39\">",
"      Augood C, Duckitt K, Templeton AA. Smoking and female infertility: a systematic review and meta-analysis. Hum Reprod 1998; 13:1532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/40\">",
"      Bolumar F, Olsen J, Boldsen J. Smoking reduces fecundity: a European multicenter study on infertility and subfecundity. The European Study Group on Infertility and Subfecundity. Am J Epidemiol 1996; 143:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/41\">",
"      Sharpe RM, Franks S. Environment, lifestyle and infertility--an inter-generational issue. Nat Cell Biol 2002; 4 Suppl:s33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/42\">",
"      Weinberg CR, Wilcox AJ, Baird DD. Reduced fecundability in women with prenatal exposure to cigarette smoking. Am J Epidemiol 1989; 129:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/43\">",
"      Storgaard L, Bonde JP, Ernst E, et al. Does smoking during pregnancy affect sons' sperm counts? Epidemiology 2003; 14:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/44\">",
"      Vine MF. Smoking and male reproduction: a review. Int J Androl 1996; 19:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/45\">",
"      Zitzmann M, Rolf C, Nordhoff V, et al. Male smokers have a decreased success rate for in vitro fertilization and intracytoplasmic sperm injection. Fertil Steril 2003; 79 Suppl 3:1550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/46\">",
"      Nizard J. [What are the epidemiological data on maternal and paternal smoking?]. J Gynecol Obstet Biol Reprod (Paris) 2005; 34 Spec No 1:3S347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/47\">",
"      Hughes EG, Lamont DA, Beecroft ML, et al. Randomized trial of a \"stage-of-change\" oriented smoking cessation intervention in infertile and pregnant women. Fertil Steril 2000; 74:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/48\">",
"      Hughes EG, Brennan BG. Does cigarette smoking impair natural or assisted fecundity? Fertil Steril 1996; 66:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/49\">",
"      Curtis KM, Savitz DA, Arbuckle TE. Effects of cigarette smoking, caffeine consumption, and alcohol intake on fecundability. Am J Epidemiol 1997; 146:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/50\">",
"      Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999-2000. JAMA 2002; 288:1723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/51\">",
"      Grodstein F, Goldman MB, Cramer DW. Body mass index and ovulatory infertility. Epidemiology 1994; 5:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/52\">",
"      Rich-Edwards JW, Goldman MB, Willett WC, et al. Adolescent body mass index and infertility caused by ovulatory disorder. Am J Obstet Gynecol 1994; 171:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/53\">",
"      Pasquali R, Gambineri A. Metabolic effects of obesity on reproduction. Reprod Biomed Online 2006; 12:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/54\">",
"      Luke B, Brown MB, Missmer SA, et al. The effect of increasing obesity on the response to and outcome of assisted reproductive technology: a national study. Fertil Steril 2011; 96:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/55\">",
"      Sallm&eacute;n M, Sandler DP, Hoppin JA, et al. Reduced fertility among overweight and obese men. Epidemiology 2006; 17:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/56\">",
"      Nguyen RH, Wilcox AJ, Skjaerven R, Baird DD. Men's body mass index and infertility. Hum Reprod 2007; 22:2488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/57\">",
"      Mitchell M, Bakos HW, Lane M. Paternal diet-induced obesity impairs embryo development and implantation in the mouse. Fertil Steril 2011; 95:1349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/58\">",
"      Hammoud AO, Gibson M, Peterson CM, et al. Impact of male obesity on infertility: a critical review of the current literature. Fertil Steril 2008; 90:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/59\">",
"      Hofny ER, Ali ME, Abdel-Hafez HZ, et al. Semen parameters and hormonal profile in obese fertile and infertile males. Fertil Steril 2010; 94:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/60\">",
"      Duits FH, van Wely M, van der Veen F, Gianotten J. Healthy overweight male partners of subfertile couples should not worry about their semen quality. Fertil Steril 2010; 94:1356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/61\">",
"      Molina RI, Martini AC, Tissera A, et al. Semen quality and aging: analysis of 9.168 samples in Cordoba. Argentina. Arch Esp Urol 2010; 63:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/62\">",
"      Galletly C, Clark A, Tomlinson L, Blaney F. Improved pregnancy rates for obese, infertile women following a group treatment program. An open pilot study. Gen Hosp Psychiatry 1996; 18:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/63\">",
"      Clark AM, Ledger W, Galletly C, et al. Weight loss results in significant improvement in pregnancy and ovulation rates in anovulatory obese women. Hum Reprod 1995; 10:2705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/64\">",
"      Norman RJ, Noakes M, Wu R, et al. Improving reproductive performance in overweight/obese women with effective weight management. Hum Reprod Update 2004; 10:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/65\">",
"      Falsetti L, Pasinetti E, Mazzani MD, Gastaldi A. Weight loss and menstrual cycle: clinical and endocrinological evaluation. Gynecol Endocrinol 1992; 6:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/66\">",
"      Clark AM, Thornley B, Tomlinson L, et al. Weight loss in obese infertile women results in improvement in reproductive outcome for all forms of fertility treatment. Hum Reprod 1998; 13:1502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/67\">",
"      Despr&eacute;s JP, Lemieux I, Prud'homme D. Treatment of obesity: need to focus on high risk abdominally obese patients. BMJ 2001; 322:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/68\">",
"      Palomba S, Falbo A, Giallauria F, et al. Six weeks of structured exercise training and hypocaloric diet increases the probability of ovulation after clomiphene citrate in overweight and obese patients with polycystic ovary syndrome: a randomized controlled trial. Hum Reprod 2010; 25:2783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/69\">",
"      Green BB, Daling JR, Weiss NS, et al. Exercise as a risk factor for infertility with ovulatory dysfunction. Am J Public Health 1986; 76:1432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/70\">",
"      Bates GW, Bates SR, Whitworth NS. Reproductive failure in women who practice weight control. Fertil Steril 1982; 37:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/71\">",
"      Gudmundsdottir SL, Flanders WD, Augestad LB. Physical activity and fertility in women: the North-Tr&oslash;ndelag Health Study. Hum Reprod 2009; 24:3196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/72\">",
"      Chavarro JE, Rich-Edwards JW, Rosner BA, Willett WC. Diet and lifestyle in the prevention of ovulatory disorder infertility. Obstet Gynecol 2007; 110:1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/73\">",
"      Wise LA, Rothman KJ, Mikkelsen EM, et al. A prospective cohort study of physical activity and time to pregnancy. Fertil Steril 2012; 97:1136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/74\">",
"      Morris SN, Missmer SA, Cramer DW, et al. Effects of lifetime exercise on the outcome of in vitro fertilization. Obstet Gynecol 2006; 108:938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/75\">",
"      Bullen BA, Skrinar GS, Beitins IZ, et al. Induction of menstrual disorders by strenuous exercise in untrained women. N Engl J Med 1985; 312:1349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/76\">",
"      Ellison PT. Salivary steroids and natural variation in human ovarian function. Ann N Y Acad Sci 1994; 709:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/77\">",
"      Puder JJ, Monaco SE, Sen Gupta S, et al. Estrogen and exercise may be related to body fat distribution and leptin in young women. Fertil Steril 2006; 86:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/78\">",
"      Prentice AM, Jebb SA. Obesity in Britain: gluttony or sloth? BMJ 1995; 311:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/79\">",
"      Rich-Edwards JW, Spiegelman D, Garland M, et al. Physical activity, body mass index, and ovulatory disorder infertility. Epidemiology 2002; 13:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/80\">",
"      Wise LA, Cramer DW, Hornstein MD, et al. Physical activity and semen quality among men attending an infertility clinic. Fertil Steril 2011; 95:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/81\">",
"      Jensen TK, Hjollund NH, Henriksen TB, et al. Does moderate alcohol consumption affect fertility? Follow up study among couples planning first pregnancy. BMJ 1998; 317:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/82\">",
"      Eggert J, Theobald H, Engfeldt P. Effects of alcohol consumption on female fertility during an 18-year period. Fertil Steril 2004; 81:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/83\">",
"      Olsen J, Bolumar F, Boldsen J, Bisanti L. Does moderate alcohol intake reduce fecundability? A European multicenter study on infertility and subfecundity. European Study Group on Infertility and Subfecundity. Alcohol Clin Exp Res 1997; 21:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/84\">",
"      Juhl M, Nyboe Andersen AM, Gr&oslash;nbaek M, Olsen J. Moderate alcohol consumption and waiting time to pregnancy. Hum Reprod 2001; 16:2705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/85\">",
"      Rostad B, Schei B, Sundby J. Fertility in Norwegian women: results from a population-based health survey. Scand J Public Health 2006; 34:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/86\">",
"      Tolstrup JS, Kjaer SK, Holst C, et al. Alcohol use as predictor for infertility in a representative population of Danish women. Acta Obstet Gynecol Scand 2003; 82:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/87\">",
"      Parazzini F, Chatenoud L, Di Cintio E, et al. Alcohol consumption is not related to fertility in Italian women. BMJ 1999; 318:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/88\">",
"      Chavarro JE, Rich-Edwards JW, Rosner BA, Willett WC. Caffeinated and alcoholic beverage intake in relation to ovulatory disorder infertility. Epidemiology 2009; 20:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/89\">",
"      Klonoff-Cohen H. Female and male lifestyle habits and IVF: what is known and unknown. Hum Reprod Update 2005; 11:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/90\">",
"      Nagy F, Pendergrass PB, Bowen DC, Yeager JC. A comparative study of cytological and physiological parameters of semen obtained from alcoholics and non-alcoholics. Alcohol Alcohol 1986; 21:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/91\">",
"      Gomathi C, Balasubramanian K, Bhanu NV, et al. Effect of chronic alcoholism on semen--studies on lipid profiles. Int J Androl 1993; 16:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/92\">",
"      Emanuele MA, Emanuele NV. Alcohol's effects on male reproduction. Alcohol Health Res World 1998; 22:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/93\">",
"      Chavarro JE, Rich-Edwards JW, Rosner BA, Willett WC. Dietary fatty acid intakes and the risk of ovulatory infertility. Am J Clin Nutr 2007; 85:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/94\">",
"      Chavarro JE, Rich-Edwards JW, Rosner BA, Willett WC. Iron intake and risk of ovulatory infertility. Obstet Gynecol 2006; 108:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/95\">",
"      Chavarro JE, Rich-Edwards JW, Rosner B, Willett WC. A prospective study of dairy foods intake and anovulatory infertility. Hum Reprod 2007; 22:1340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/96\">",
"      Chavarro JE, Rich-Edwards JW, Rosner BA, Willett WC. Protein intake and ovulatory infertility. Am J Obstet Gynecol 2008; 198:210.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/97\">",
"      Chavarro JE, Rich-Edwards JW, Rosner BA, Willett WC. Use of multivitamins, intake of B vitamins, and risk of ovulatory infertility. Fertil Steril 2008; 89:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/98\">",
"      Toledo E, Lopez-del Burgo C, Ruiz-Zambrana A, et al. Dietary patterns and difficulty conceiving: a nested case-control study. Fertil Steril 2011; 96:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/99\">",
"      Vujkovic M, de Vries JH, Lindemans J, et al. The preconception Mediterranean dietary pattern in couples undergoing in vitro fertilization/intracytoplasmic sperm injection treatment increases the chance of pregnancy. Fertil Steril 2010; 94:2096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/100\">",
"      Mendiola J, Torres-Cantero AM, Moreno-Grau JM, et al. Food intake and its relationship with semen quality: a case-control study. Fertil Steril 2009; 91:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/101\">",
"      Zampieri N, Zamboni C, Ottolenghi A, Camoglio FS. The role of lifestyle changing to improve the semen quality in patients with varicocele. Minerva Urol Nefrol 2008; 60:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/102\">",
"      Sowers MR, Crawford S, McConnell DS, et al. Selected diet and lifestyle factors are associated with estrogen metabolites in a multiracial/ethnic population of women. J Nutr 2006; 136:1588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/103\">",
"      Grodstein F, Goldman MB, Ryan L, Cramer DW. Relation of female infertility to consumption of caffeinated beverages. Am J Epidemiol 1993; 137:1353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/104\">",
"      Matthiesen SM, Frederiksen Y, Ingerslev HJ, Zachariae R. Stress, distress and outcome of assisted reproductive technology (ART): a meta-analysis. Hum Reprod 2011; 26:2763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?11/13/11482/abstract/105\">",
"      Buck GM, Sever LE, Batt RE, Mendola P. Life-style factors and female infertility. Epidemiology 1997; 8:435.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5411 Version 21.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.243-2BB6473422-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_13_11482=[""].join("\n");
var outline_f11_13_11482=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      NORMAL FERTILITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Fertile period and frequency of coitus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Effect of age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      LIMITATIONS OF DATA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      TOBACCO USE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H647595133\">",
"      Female partner",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H647595140\">",
"      Male partner",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Cessation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      BODY MASS INDEX",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H647595147\">",
"      Female partner",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H647595154\">",
"      Male partner",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Optimum weight",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      EXERCISE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4029032\">",
"      Female partner",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20448227\">",
"      Male partner",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      ALCOHOL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H647595161\">",
"      Female partner",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H647595168\">",
"      Male partner",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Optimum intake",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      DIET",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      CAFFEINE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H647595203\">",
"      Female partner",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H647595210\">",
"      Male partner",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Suggested intake",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      STRESS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      ENVIRONMENTAL TOXINS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      RECREATIONAL OR ILLICIT DRUGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      LIFESTYLE EFFECTS ON ESTABLISHED PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      FUTURE DIRECTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/5411\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5411|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/24/11661\" title=\"figure 1\">",
"      Fecundability in healthy couples",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/45/43741\" title=\"figure 2\">",
"      Pregnant rate smoke vs nonsmoke",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/3/12351\" title=\"figure 3\">",
"      Nomogram for BMI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5411|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/33/539\" title=\"table 1\">",
"      Probability of pregnancy after unprotected intercourse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/22/367\" title=\"table 2A\">",
"      Determining BMI A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/9/157\" title=\"table 2B\">",
"      Determining BMI B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/43/31422\" title=\"table 3\">",
"      Caffeine content",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?39/41/40593?source=related_link\" title=\"calculator 1\">",
"      Calculator: Body mass index (BMI; Quetelet's index)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/38/41575?source=related_link\">",
"      Alcohol intake and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/3/36919?source=related_link\">",
"      Amenorrhea and infertility associated with exercise",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/18/3367?source=related_link\">",
"      Causes of female infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/36/39495?source=related_link\">",
"      Diagnosis of polycystic ovary syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/2/23593?source=related_link\">",
"      Eating disorders: Epidemiology, pathogenesis, clinical features, and course of illness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/7/31865?source=related_link\">",
"      Effect of advanced age on fertility and pregnancy in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/54/30567?source=related_link\">",
"      Effect of advanced paternal age on fertility and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/61/40921?source=related_link\">",
"      Evaluation of female infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/44/33481?source=related_link\">",
"      Evaluation of male infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/6/26724?source=related_link\">",
"      Evaluation of the menstrual cycle and timing of ovulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/35/30266?source=related_link\">",
"      Health hazards associated with obesity in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/4/28746?source=related_link\">",
"      Infants of mothers with substance abuse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/40/4746?source=related_link\">",
"      Occupational and environmental risks to reproduction in females",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/12/6346?source=related_link\">",
"      Overview of illicit drug use in pregnant women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/56/17287?source=related_link\">",
"      Overview of infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/3/23609?source=related_link\">",
"      Overview of smoking cessation management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/46/28394?source=related_link\">",
"      Overview of the benefits and risks of exercise",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/61/38874?source=related_link\">",
"      Overview of the risks and benefits of alcohol consumption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/45/13016?source=related_link\">",
"      Overview of therapy for obesity in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40650?source=related_link\">",
"      Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/25/16794?source=related_link\">",
"      Preconception evaluation and counseling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/12/35018?source=related_link\">",
"      Prevention of sexually transmitted infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/52/22343?source=related_link\">",
"      Psychological stress and infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/20/12615?source=related_link\">",
"      Screening for and clinical evaluation of obesity in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/62/22505?source=related_link\">",
"      Secondhand smoke exposure: Effects in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/53/27482?source=related_link\">",
"      Smoking and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/23/19834?source=related_link\">",
"      Spontaneous abortion: Risk factors, etiology, clinical manifestations, and diagnostic evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/35/20026?source=related_link\">",
"      The effects of caffeine on reproductive outcomes in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/11/29882?source=related_link\">",
"      The impact of obesity on fertility and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3610?source=related_link\">",
"      Treatment of male infertility",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f11_13_11483="Assessment of severity of diabetic ketoacidosis in children";
var content_f11_13_11483=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F72608&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F72608&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Assessment of severity of diabetic ketoacidosis in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mild",
"       </td>",
"       <td class=\"subtitle1\">",
"        Moderate",
"       </td>",
"       <td class=\"subtitle1\">",
"        Severe",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Defining features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Venous pH",
"       </td>",
"       <td>",
"        7.2-7.3",
"       </td>",
"       <td>",
"        7.1-7.2",
"       </td>",
"       <td>",
"        &lt;7.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Serum bicarbonate (mEq/L)",
"       </td>",
"       <td>",
"        10-15",
"       </td>",
"       <td>",
"        5-10",
"       </td>",
"       <td>",
"        &lt;5",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Wolfsdorf J, Glaser N, Sperling MA, American Diabetes Association. Diabetic ketoacidosis in infants, children, and adolescents: A consensus statement from the American Diabetes Association. Diabetes Care 2006; 29:1150.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_13_11483=[""].join("\n");
var outline_f11_13_11483=null;
var title_f11_13_11484="Autoimmune blistering diseases";
var content_f11_13_11484=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F76641&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F76641&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Autoimmune mucocutaneous blistering diseases",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Pemphigoid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Bullous pemphigoid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Mucous membrane pemphigoid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Pemphigoid gestationis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Anti-laminin 332 pemphigoid (anti-epiligrin cicatricial pemphigoid)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Anti-laminin &gamma;1 pemphigoid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Other pemphigoid variants",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Linear IgA disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Linear IgA bullous dermatosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Chronic bullous disease of childhood",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Pemphigus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Pemphigus vulgaris",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        <ul>",
"         <li>",
"          Pemphigus vegetans",
"         </li>",
"         <li>",
"          Pemphigus herpetiformis",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Pemphigus foliaceus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        <ul>",
"         <li>",
"          Pemphigus erythematosus",
"         </li>",
"         <li>",
"          Fogo selvagem",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Paraneoplastic pemphigus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        IgA pemphigus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        <ul>",
"         <li>",
"          Subcorneal pustular dermatosis",
"         </li>",
"         <li>",
"          Intraepidermal neutrophilic IgA dermatosis",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bullous lupus erythematosus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dermatitis herpetiformis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Epidermolysis bullosa acquisita",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_13_11484=[""].join("\n");
var outline_f11_13_11484=null;
var title_f11_13_11485="Outbreaks of yersiniosis";
var content_f11_13_11485=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F73764&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F73764&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Signs, symptoms, and outcome in outbreaks of yersiniosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        New York state*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Southern US&bull;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Washington state&Delta;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Georgia&loz;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Time period",
"       </td>",
"       <td>",
"        1976",
"       </td>",
"       <td>",
"        1982",
"       </td>",
"       <td>",
"        1981-82",
"       </td>",
"       <td>",
"        1988-89",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Median age, years",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        &lt;1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Number of patients",
"       </td>",
"       <td>",
"        38",
"       </td>",
"       <td>",
"        172",
"       </td>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Serotype",
"       </td>",
"       <td>",
"        O:8",
"       </td>",
"       <td>",
"        O13a, 13b",
"       </td>",
"       <td>",
"        O:8",
"       </td>",
"       <td>",
"        O:3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"5\" rowspan=\"1\">",
"        Percent with:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Diarrhea",
"       </td>",
"       <td class=\"sublist1\">",
"        47",
"       </td>",
"       <td class=\"sublist1\">",
"        83",
"       </td>",
"       <td class=\"sublist1\">",
"        86",
"       </td>",
"       <td class=\"sublist1\">",
"        100",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Bloody diarrhea",
"       </td>",
"       <td class=\"sublist1\">",
"        -",
"       </td>",
"       <td class=\"sublist1\">",
"        20",
"       </td>",
"       <td class=\"sublist1\">",
"        30",
"       </td>",
"       <td class=\"sublist1\">",
"        60",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Abdominal pain",
"       </td>",
"       <td class=\"sublist1\">",
"        97",
"       </td>",
"       <td class=\"sublist1\">",
"        86",
"       </td>",
"       <td class=\"sublist1\">",
"        96",
"       </td>",
"       <td class=\"sublist1\">",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Fever",
"       </td>",
"       <td class=\"sublist1\">",
"        100",
"       </td>",
"       <td class=\"sublist1\">",
"        93",
"       </td>",
"       <td class=\"sublist1\">",
"        91",
"       </td>",
"       <td class=\"sublist1\">",
"        100",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Vomiting",
"       </td>",
"       <td class=\"sublist1\">",
"        -",
"       </td>",
"       <td class=\"sublist1\">",
"        41",
"       </td>",
"       <td class=\"sublist1\">",
"        42",
"       </td>",
"       <td class=\"sublist1\">",
"        27",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Sore throat",
"       </td>",
"       <td class=\"sublist1\">",
"        -",
"       </td>",
"       <td class=\"sublist1\">",
"        22",
"       </td>",
"       <td class=\"sublist1\">",
"        2",
"       </td>",
"       <td class=\"sublist1\">",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"5\" rowspan=\"1\">",
"        Outcome, percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hospitalization",
"       </td>",
"       <td class=\"sublist1\">",
"        95",
"       </td>",
"       <td class=\"sublist1\">",
"        -",
"       </td>",
"       <td class=\"sublist1\">",
"        30",
"       </td>",
"       <td class=\"sublist1\">",
"        47",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Surgery",
"       </td>",
"       <td class=\"sublist1\">",
"        42",
"       </td>",
"       <td class=\"sublist1\">",
"        10",
"       </td>",
"       <td class=\"sublist1\">",
"        6",
"       </td>",
"       <td class=\"sublist1\">",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Death",
"       </td>",
"       <td class=\"sublist1\">",
"        0",
"       </td>",
"       <td class=\"sublist1\">",
"        0",
"       </td>",
"       <td class=\"sublist1\">",
"        0",
"       </td>",
"       <td class=\"sublist1\">",
"        0",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     Dash indicates data were not collected.",
"     <span style=\"font-style:italic\">",
"     </span>",
"    </div>",
"    <div class=\"reference\">",
"     * Black, RE, Jackson, RJ, Tsai, T, et al, N Engl J Med 1978; 298:76.",
"     <br>",
"      &bull; Tacket, CO, Narain, JP, Sattin, R, et al, JAMA 1984; 251:483.",
"      <br>",
"       &Delta; Tacket, CO, Ballard, J, Harris, N, et al, Am J Epidemiol 1985; 121:705.",
"       <br>",
"        &loz; Lee, LA, Gerber, R, Lonsway, DR, et al, N Engl J Med 1990; 322:984.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_13_11485=[""].join("\n");
var outline_f11_13_11485=null;
var title_f11_13_11486="Mortality men women AF";
var content_f11_13_11486=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F71640&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F71640&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Atrial fibrillation increases mortality in men and women",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 406px; height: 260px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Among 5209 subjects in the Framingham Heart Study, the mortality after a 10-year follow-up was higher in both men and women, aged 55 to 74, who had atrial fibrillation (AF) compared to those without AF (p &lt;0.001) A similar relationship was seen in subjects between the ages of 75 and 94 (not shown).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Benjamin EJ, Wolf PA, D'Agostino RB, et al. Circulation 1998; 98:946.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f11_13_11486=[""].join("\n");
var outline_f11_13_11486=null;
var title_f11_13_11487="Contents: Chemotherapeutic agents";
var content_f11_13_11487=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?3/43/3774\">",
"       Oncology",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Chemotherapeutic agents",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Chemotherapeutic agents",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Chemotherapy regimens",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/41/25233\">",
"           Treatment protocols for bladder cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/15/17650\">",
"           Treatment protocols for breast cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/56/17281\">",
"           Treatment protocols for castration-resistant prostate cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/45/10963\">",
"           Treatment protocols for colorectal cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/23/43378\">",
"           Treatment protocols for esophagogastric cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/25/19858\">",
"           Treatment protocols for germ cell tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/20/31043\">",
"           Treatment protocols for gynecologic malignancies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/48/34561\">",
"           Treatment protocols for hepatobiliary cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/44/24258\">",
"           Treatment protocols for lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/45/44753\">",
"           Treatment protocols for multiple myeloma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/14/6370\">",
"           Treatment protocols for non-small cell lung cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/42/32417\">",
"           Treatment protocols for pancreatic cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/12/6337\">",
"           Treatment protocols for renal cell cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/28/18881\">",
"           Treatment protocols for small-cell carcinoma of the lung",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/15/7410\">",
"           Treatment protocols for soft tissue and bone sarcoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/56/25473\">",
"           Treatment protocols for squamous cell carcinoma of the head and neck",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Side effects",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/29/8665\">",
"           Autoimmune complications following purine analog therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/31/12794\">",
"           Bleomycin-induced lung injury",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/34/37415\">",
"           Busulfan-induced pulmonary injury",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/62/11242\">",
"           Cancer-related fatigue: Prevalence, screening and clinical assessment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/29/27098\">",
"           Cancer-related fatigue: Treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/46/41706\">",
"           Cardiotoxicity of anthracycline-like chemotherapy agents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/12/40138\">",
"           Cardiotoxicity of nonanthracycline cancer chemotherapy agents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/15/42232\">",
"           Cardiotoxicity of trastuzumab",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/2/44074\">",
"           Chemotherapy hepatotoxicity and dose modification in patients with liver disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/12/44232\">",
"           Chemotherapy-induced alopecia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/48/41738\">",
"           Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/26/41380\">",
"           Chlorambucil-induced pulmonary injury",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/8/29833\">",
"           Cisplatin nephrotoxicity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/2/34857\">",
"           Crystal-induced acute kidney injury (acute renal failure)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/7/36986\">",
"           Cutaneous complications of conventional chemotherapy agents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/63/35834\">",
"           Cutaneous complications of molecularly targeted therapy and other biologic agents used for cancer therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/30/21990\">",
"           Cyclophosphamide pulmonary toxicity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/39/23161\">",
"           Cystitis in patients with cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/32/37384\">",
"           Differentiation (retinoic acid) syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/24/13706\">",
"           Effects of cytotoxic agents on gonadal function in adult men",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/23/42362\">",
"           Enterotoxicity of chemotherapeutic agents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/13/218\">",
"           Extravasation injury from chemotherapy and other non-neoplastic vesicants",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/32/25098\">",
"           General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/26/37285\">",
"           Heavy or irregular uterine bleeding during chemotherapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/22/23914\">",
"           Hematologic consequences of malignancy: Anemia and bleeding",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/57/43930\">",
"           Infusion reactions to systemic chemotherapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/19/38202\">",
"           Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/5/9306\">",
"           Methotrexate-induced lung injury",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/46/33513\">",
"           Mitomycin-C pulmonary toxicity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/3/43064\">",
"           Neurologic complications of cancer treatment with biologic agents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/32/43530\">",
"           Neurologic complications of non-platinum cancer chemotherapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/23/37242\">",
"           Neurologic complications of platinum-based chemotherapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/42/28327\">",
"           Nitrosourea-induced pulmonary injury",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/22/38250\">",
"           Oral toxicity associated with chemotherapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/26/1447\">",
"           Ovarian failure due to anticancer drugs and radiation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/61/39894\">",
"           Pathophysiology and prediction of chemotherapy-induced nausea and vomiting",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/18/39210\">",
"           Prevention and treatment of chemotherapy-induced nausea and vomiting",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/59/3001\">",
"           Prophylaxis of infection during chemotherapy-induced neutropenia in high-risk adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/14/7401\">",
"           Pubertal development and gonadal function in survivors of childhood cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/41/17050\">",
"           Pulmonary toxicity associated with antineoplastic therapy: Cytotoxic agents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/49/29466\">",
"           Pulmonary toxicity associated with antineoplastic therapy: Molecularly targeted agents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/42/13993\">",
"           Pulmonary toxicity associated with systemic antineoplastic therapy: Clinical presentation, diagnosis, and treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/43/39610\">",
"           Risks of therapy with bone modifying agents in patients with advanced malignancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/15/38138\">",
"           Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/42/10922\">",
"           Systemic chemotherapy for cancer in elderly persons",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/28/38344\">",
"           Taxane-induced pulmonary toxicity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/55/33658\">",
"           Therapeutic use and toxicity of high-dose methotrexate",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/43/36538\">",
"           Toxicity of molecularly targeted antiangiogenic agents: Cardiovascular effects",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/54/43882\">",
"           Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/49/20250\">",
"           Treatment-related toxicity in men with testicular germ cell tumors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/1/19481\">",
"           Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/20/3402\">",
"           Tumor lysis syndrome: Prevention and treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/9/33945\">",
"           Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-6C1552FF95-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f11_13_11487=[""].join("\n");
var outline_f11_13_11487=null;
